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Abstract: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease caused by the
malignant transformation of immature progenitors primed towards T-cell development. Clinically,
T-ALL patients present with diffuse infiltration of the bone marrow by immature T-cell blasts high
blood cell counts, mediastinal involvement, and diffusion to the central nervous system. In the past
decade, the genomic landscape of T-ALL has been the target of intense research. The identification
of specific genomic alterations has contributed to identify strong oncogenic drivers and signaling
pathways regulating leukemia growth. Notwithstanding, T-ALL patients are still treated with
high-dose multiagent chemotherapy, potentially exposing these patients to considerable acute and
long-term side effects. This review summarizes recent advances in our understanding of the signaling
pathways relevant for the pathogenesis of T-ALL and the opportunities offered for targeted therapy.
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1. Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological tumor arising from
the malignant transformation and subsequent clonal expansion of T-cell precursors expressing
immature T-cell markers. Based on the maturational stage of normal thymic development at
which transformation occurs, T-ALL can be classically sub-classified into early cortical, late cortical
or mature [1]. Recently, a new subgroup called Early T-lineage progenitor T-ALL (ETP-ALL) which
shows a block at the earliest stages of T-cell differentiation and lacks expression of several T-cell surface
markers [Cluster of Differentiation (CD)1a, CD8, and CD5] but instead expresses myeloid and stem
cell markers, has been described [2,3]. T-ALL accounts for 25% of adult and 15% of pediatric ALL cases,
with cure rates respectively reaching 60% and over 80% of the patients thanks to current intensive
chemotherapy protocols [4]. However, primary resistance to treatment and relapse are observed in
a significant number of patients, for which prognosis remains poor, underscoring the need of more
efficient and specific treatments.
At the molecular level T-ALL is a heterogeneous disease, where a wide spectrum of genetic
lesions [5] and microenvironmental factors [6] cooperate to promote a multistep leukemogenic process,
altering normal cell growth, survival, proliferation, and differentiation during thymocyte development.
Notwithstanding, genetic alterations that activate neurogenic locus notch homolog protein 1 (NOTCH1)
signaling and T-cell transcription factors, coupled with inactivation of the inhibitors of CDK4/alternate
reading frame (INK4/ARF) tumor suppressors, are hallmarks of T-ALL [5,7,8]. Despite the prominent
role of cell-intrinsic mechanisms in T-cell transformation, T-ALL cell growth is not fully cell
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autonomous and it is becoming clear that the metabolic milieu of the microenvironment dictates
the behavior of tumors.
In this review, we summarize and discuss recent advances in understanding the signal
transduction pathways that are de-regulated in T-ALL, the emerging role in cancer development
of leukemic adaptation to metabolic stresses encountered in the native environment and evaluate their
potential as therapeutic targets.
2. Normal T Lymphocyte Development
Differently from other hematopoietic lineages, development of T-cells from pluripotent
hematopoietic stem cells takes place in the thymus. Early T-cell progenitors enter the thymus at
the cortico-medullary junction [9] where they encounter instructive signals inducing cell growth and
proliferation mainly through stimuli such as interleukin-7 (IL-7) [10,11] and stem cell factor (SCF) [12].
These uncommitted lymphoid progenitors activate NOTCH1 signaling while circulating along the
thymic cortex, thus receiving instructive signals leading to cell lineage commitment toward a T-cell
fate [13]. Several developmental stages of thymocyte differentiation can be distinguished through
cell surface markers [14]. Thymocytes are primarily subdivided into double negative (DN), double
positive (DP) and single positive (SP) subsets in relation to the expression of the molecules CD4
and CD8. The most immature thymocytes (early uncommitted thymocytes), named DN, can be
subdivided into four stages of differentiation based on the expression of CD44 and CD25 (recently
reviewed in Shah and Zúniga-Pflücker [15]). During the DN3 (CD44−CD25+) stage of development,
the expression of a constitutively active pre-T cell receptor (pre-TCR; composed of the invariable pre-T
alpha chain and the rearranged TCRβ chain) [16], induces very high levels of NOTCH1 signaling
leading to marked cell proliferation. DN3 thymocytes then progress to DN4 cells (CD44−CD25−)
and then intermediate single-positive (ISP) cells, a transition population that expresses a co-receptor
(CD4 in humans or CD8 in mice) in the absence of high levels of surface CD3. NOTCH1 activation
in these rapidly proliferating pre-TCR expressing T-cell committed progenitors in combination with
Phosphatidylinositol 3-kinase (PI3K) signaling [17] is critical for supporting their maturation to CD4 +
CD8+ DP cells. T-cell commitment towards the T-cell receptor alpha/beta (TCRαβ) positive lineage
takes place during DN stages of development at which gamma delta (γδ) T-cells split off. When
thymocyte precursors differentiate to DP cells, they cease to proliferate and rearrange their TCRα
loci. These cells represent about 85% of all thymocytes and most express CD1a. After undergoing
positive checkpoint selection (capacity of DP T-cells to recognize self-major histocompatibility complex
(MHC) molecules) and negative checkpoint selection (capacity to recognize self-peptide loaded MHCs
without eliciting an autoimmune-prone response), thymocytes that express functional TCRs commit
to either CD4 or CD8 SP lineage. SP CD4+ and CD8+ cells that survive negative selection leave the
thymus and populate the peripheral lymphoid tissues.
3. Genetics of T-ALL
Among the genetic abnormalities, chromosomal translocations of transcription factor genes
to regulatory regions of T-cell receptor genes are frequent and characteristic events of T-ALL. These
transcription factors include basic helix-loop-helix (bHLH) family members such as T-cell acute
lymphobastic leukemia 1 (TAL1) [18], TAL2 [19], lymphoblastic leukaemia associated haematopoietic
regulator 1 (LYL1) [20], and Basic Domain, Helix-Loop-Helix Protein, Class B, 1 (BHLHBL1) [also
known as Oligodendrocyte Transcription Factor 2 (OLIG2)] [21]; LIM-only domain (LMO) genes
(LMO1 and LMO2) [22,23]; homeobox (HOX) transcription factors such as T-cell leukemia homeobox 1
(TLX1/HOX11) [24], TLX3 (HOX11L2) [25], NK2 homeobox NKX2-1, NKX2-2 and NKX2-5 [26,27],
and homeobox A (HOXA) cluster [28]; and proto-oncogenes such as avian myelocytomatosis viral
oncogene homolog MYC [29] and myeloblastosis transcriptional activator (MYB) [30,31]. In addition,
mutations and deletions in tumor suppressor genes such as Wilms Tumor 1 (WT1), Lymphoid
Enhancer Binding Factor 1 (LEF1), ETS Variant 6 (ETV6), B-Cell CLL/Lymphoma 11B (BCL11B),
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Runt Related Transcription Factor 1 (RUNX1) and GATA Binding Protein 3 (GATA3) contribute to
the overall transcriptional deregulation of T-ALL, extensively reviewed in [5]. Activating mutations
of NOTCH1 are present in at least 60% of T-ALL [7], while rare additional rearrangements result in the
expression of chimeric fusion genes involving Lysine Methyltransferase 2A (KMT2A)/Mixed Lineage
Leukemia 1 (MLL1), HOXA genes, and tyrosine kinase genes such as Abelson murine leukemia viral
oncogene homolog 1 (ABL1) [32,33]. Deletions involving the cyclin-dependent kinase inhibitor 2A/2B
(CDKN2A/CDKN2B) cell cycle regulator loci are highly prevalent (>70% of T-ALL cases [8]); rarer
chromosomal deletions recurrently inactivate retinoblastoma gene 1 (RB1) and cyclin-dependent kinase
inhibitor 1B (CDKN1B) in some cases of T-ALL [31,34]. Several genes encoding epigenetic regulators
and chromatin modifiers are also recurrently mutated in T-ALL, including Enhancer of zeste homolog 2
(EZH2), suppressor of zeste 12 homolog (SUZ12) and embryonic ectoderm development (EED) [35],
which are members of the polycomb repressor complex 2 (PRC2); the plant homeodomain factor gene
PHF6 [36]; the histone demethylase lysine demethylase 6A (KDM6A) [37]; and the deubiquitinating
enzyme ubiquitin specific peptidase 7 (USP7) [38].
4. T-ALL Molecular Subgroups
All classification schemes of T-ALL are essentially based on a comparison with normal T-cell
development [39]. Moreover, gene expression profiling studies have helped in the identification
of T-ALL molecular subgroups that are characterized by specific transcriptional profiles and aberrant
expression of specific T-ALL transcription factor oncogenes, often as a consequence of a chromosomal
defect [1,40]. The largest subgroup is defined by ectopic TAL1 expression (in some cases together with
LMO1/LMO2) characterized by a mature late cortical thymocyte immunophenotype (CD4+ CD8+
CD3+). Other major subgroups show mutually exclusive expression of TLX1, TLX3, HOXA9/10, LMO2,
or NKX-2 [26,28]. Leukemias associated with TLX1, TLX3 or NKX-1,-2 activation have an early cortical
immunophenotype (CD1a+ CD4+ CD8+). Furthermore, the ETP-ALL subgroup showing a block at
the earliest stages of T-cell differentiation (CD4− CD8− cells) has been described and corresponds
to immature T-ALLs expressing stem cell genes. This subgroup frequently shows aberrant expression
of LMO2/LYL1 [1,41].
Recent sequencing studies have suggested that between 10 and 20 protein sequence altering
mutations are present in T-ALL cells [42–44]. This sequential increase in mutational burden does
not seem to occur randomly, as specific combinations of mutations are often found [41,45]. In fact,
mutations affecting the PI3K/v-akt murine thymoma viral oncogene homolog (AKT) pathway
(phosphatase and tensin homolog/PTEN, phosphoinositide-3-kinase regulatory subunit 1/PIK3R1)
are highly prevalent in TAL1+ cases, suggesting a strong pressure for PTEN inactivation to occur
in these cells, and that TAL1 over-expression cooperates with mutations affecting the PI3K/AKT
pathway (especially PTEN inactivation) to promote T-cell transformation. Conversely, interleukin 7
receptor/Janus kinase/signal transducer and activator of transcription (IL-7R/JAK/STAT) signaling
pathway or rat sarcoma viral oncogene homolog (RAS) mutations are frequently observed in immature
T-ALL cases or TLX1/TLX3+ and HOXA+ cases. ETP-ALL shows genetically a lower prevalence
of NOTCH1 mutations and CDKN2A deletions, instead has a high prevalence of mutations in
genes implicated in JAK/STAT signaling, Ras signaling and epigenetic regulation. Other interesting
observations include, association between mutations in the putative epigenetic regulators PHD finger
protein 6 (PHF6) [36], CCCTC-binding factor (CTCF) [41], KMT2A [41] and WT1 [46] with the TLX3
rearrangement; mutations in the ubiquitin-specific protease USP7 and TAL1+ cases; and mutations
in protein phosphatase non-receptor type 2 (PTPN2) and TLX1+ cases [41].
5. Signaling Pathways Involved in the Development of T-ALL
The proliferative and survival advantages of T-ALL blasts result from altered signaling pathways
which are frequently shared across the different molecular subgroups and crosstalk to promote
disease progression (Figure 1). Frequently, the aberrant activation of these signaling pathways
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crucial to normal T-cell development and implicated in the pathogenesis of T-ALL, is due to genetic
alterations of components of these pathways. However, it is becoming clear that bidirectional cross-talk
between the microenvironment and leukemic cells exists and that microenvironmental cues ultimately
contribute to tumor cell proliferation and survival [47]. Amongst the intracellular signaling pathways
activated by genetic alterations (excluding oncogenic NOTCH1 signaling and CDKN2A/CDKN2B
alterations) we find: (1) increased kinase signaling through: (i) the PI3K/AKT/mechanistic
target of rapamycin (mTOR) [PI3K/AKT/mTOR] pathway, most commonly altered by PTEN
deletion/mutations, PTPN2 deletion, PIK3R1 or v-akt murine thymoma viral oncogene homolog 1
(AKT1) mutations; (ii) the IL-7R/JAK/STAT pathway, via activating mutations in the interleukin 7
receptor α-chain gene (IL-7Rα), Janus kinase 1 (JAK1), JAK3 or signal transducer and activator of
transcription 5B (STAT5B); (iii) the RAS/mitogen-activated protein kinase (RAS/MAPK) signaling
through Kirsten rat sarcoma viral oncogene homolog (KRAS) and neurofibromin 1 (NF1) mutations;
and (iv) via chimeric ABL1 fusion genes such as nucleoporin 214kDa-Abelson murine leukemia viral
oncogene homolog 1 (NUP214)-ABL1 and ETS Variant 6-Abelson murine leukemia viral oncogene
homolog 1 (ETV6)-ABL1; (2) altered epigenetic regulation through mutations affecting (i) PHF6;
(ii) PRC2 components EZH2, SUZ12 and EED; (iii) KMT2A [also called ubiquitously transcribed
tetratricopeptide repeat, X chromosome (UTX)] reviewed in [48]; (3) altered ribosomal function through
mutations affecting Ribosomal protein L5 (RPL5), Ribosomal protein L10 (RPL10), Ribosomal protein
L22 (RPL22) or CCR4-NOT transcription complex subunit 3 (CNOT3) [43]; and (4) altered expression
of oncogenic miRNAs (onco-miRs) such as miR-19b, miR-20a, miR-26a, miR-92, and miR-223 or long
noncoding RNAs (lncRNAs) such as leukemia-induced non coding activator RNA 1 (LUNAR1) [45].
On the other hand, cell-extrinsic microenvironmental factors such as nutrient availability, hypoxia,
chemokines, growth factors and their receptors promote tumor growth through the activation of
specific signal transduction pathways including PI3K/AKT/mTOR signaling, AMP-activated protein
kinase (AMPK) signaling, Hedgehog signaling, calcineurin/nuclear factors of activated T-cells (NFAT)
signaling, Wnt signaling and hypoxia-inducible factor (HIF-1) signaling.
5.1. Oncogenic NOTCH Signaling and NOTCH1-Myc Signaling Axis
The NOTCH1 signaling pathway is critical in the thymus for early T-cell fate specification and
thymocyte development [49]. Aberrant activation of the NOTCH1 signaling cascade in T-ALL was
first identified through the finding of a rare chromosomal translocation t(7; 9) (q34; q34.3) which
determined the expression of a constitutively active form of NOTCH1 (Translocation associated notch
protein 1; TAN-1) downstream of the TCRβ promoter [50]. However, this is a rare event and it took
several years before NOTCH1 signaling entered the center stage of T-ALL biology. In fact, it was
not until the year 2004, that activating mutations in NOTCH1 were identified in over 60% of T-ALL
cases [7]. A recent report using an integrated genomic approach in 264 T-ALL cases found an even
higher frequency of NOTCH1 mutations (≈75%) [41]. In addition, 8–30% of T-ALLs harbor mutations
in F-box and beta-transducin (WD) repeat domain containing 7 (FBXW7), a protein that normally
promotes NOTCH1 proteasomal degradation, and lead to increased NOTCH1 protein stability [51,52].
Moreover, paracrine mechanisms that result in NOTCH1 or neurogenic locus notch homolog protein 3
(NOTCH3) signaling upregulation or rare mutations in NOTCH3 [53] may contribute to T-ALL. Thus,
aberrant expression of the NOTCH ligand delta-like 4 (DLL4) may contribute to NOTCH1-driven
leukemias [54]. The role of NOTCH1 signaling in the context of T-ALL and its intricate and complex
interaction with c-MYC is discussed in detail in a recent review [55]. Here, we only discuss some of the
main therapeutic implications of this signaling axis.
NOTCH promotes leukemia cell growth through direct transcriptional upregulation of anabolic
pathways, including ribosome biosynthesis, protein translation and nucleotide and amino acid
metabolism [56,57]. These growth-promoting effects of the NOTCH1 transcriptional program
are enhanced by the upregulation of the MYC oncogene, a direct target of NOTCH1 [56,58,59].
Moreover, abrogation of oncogenic NOTCH1 signaling induces a metabolic crisis, which includes
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transcriptional down-regulation of anabolic genes, upregulation of catabolic pathways (ubiquitination,
proteasome degradation), decreased glycolytic and glutaminolitic flux, and increased autophagy [58].
Interestingly, NOTCH1-dependent T-ALL cells are addicted to glutamine for cell growth, and genetic
or pharmacological inhibition of glutaminase (enzyme that converts glutamine to glutamate for
further processing in the Krebs cycle) has strong synergistic antitumor effects in combination with
NOTCH1 inhibition.
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Figure 1. Schematic representation of signaling pathways aberrantly activated in T-cell acute
lymphoblastic leukemia (T-ALL), tentatively subdivided as being mainly due to cell-extrinsic (shaded
green) and cell-intrinsic factors (shaded red) or mixed (green and red).
The high prevalence of T-ALL cases having aberrant activation of the NOTCH-signaling pathway
provides the rationale for the development of targeted therapies aimed at inhibiting NOTCH signaling
in this disease [55]. Amongst the strategies adopted are: (i) the use of inhibitors of the proteolytic
cleavage of the transmembrane NOTCH1 receptor by the presenilin/γ-secretase complex using
γ-secretase inhibitors (GSIs), alone or in combination with vincristine or dexamethasone [60–62];
(ii) specific NOTCH1 inhibitory antibodies binding the negative regulatory region (NRR) of
the NOTCH1 receptor [63,64]; (iii) stapled peptides such as SAHM1 that target the NOTCH1
transcriptional complex [65]; (iv) therapeutic targeting of downstream NOTCH pathway components
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such as the transcriptional target insulin-like growth factor receptor (IGF1R) [66] or (iv) inhibition
of sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) channels with thapsigargin which
impairs the surface expression of mature NOTCH1 protein with preferential suppression of mutant
NOTCH1 receptors [67]. Finally, hairy and enhancer of split 1 homolog (HES1) which plays an
important role in T-cell development [68] and NOTCH1-induced leukemia, was recently confirmed as
a critical downstream component of NOTCH1 signaling [69]. Interestingly, in this study perhexiline
(a carnitine O-palmitoyltransferase 1 inhibitor, used in the treatment of angina) was able to evoke
a strong anti-leukemic response in vitro and in vivo possibly by reverting the HES1 driven gene
signature, providing a new lead for drug repurposing.
MYC is a master transcriptional factor that increases catabolism and is deregulated in numerous
human cancers [70]. In early T-cell development, MYC controls cell growth downstream
of NOTCH1 and pre-TCR signaling [71]. Although MYC has been shown to be a critical mediator
of NOTCH1-dependent transformation [56,57,72], direct involvement of MYC overexpression in T-cell
transformation was initially thought to occur only rarely due to translocations of MYC to the
TCRα and TCRδ loci. Recently, however, the identification of massive binding of NOTCH1 at
a distal enhancer near the MYC locus (NOTCH1-controlled MYC enhancer (N-Me)) has formally
established a direct role for NOTCH1 in controlling MYC expression [58,59]. Moreover, recurrent
somatically acquired focal duplications of the N-Me were found in 5% of T-ALL cases, providing
an example of genetic alterations targeting oncogenic enhancer activity in T-ALL. MYC promotes
cell transformation not only through increased cell growth and proliferation but also sustaining
leukemia-initiating activity [73]. As mentioned above, MYC (and other oncogenic driver genes)
may be aberrantly expressed through the intervention of super enhancers [74], broad areas of
open chromatin characterized by high occupancy by bromodomain containing 4 (BRD4), p300,
histone H3 lysine 27 (H3K27) acetylation, and the Mediator complex. Impacting on the activity
of these large enhancers with molecules such as the BRD4 inhibitor S-Tert-butyl2-(4-(4-chlorophenyl)-
2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate(JQ1), may provide new
opportunities for blocking oncogenic transcriptional networks [75].
5.2. PI3K/AKT/mTOR Pathway
The phosphoinositide 3-kinase (PI3K) pathway is one of the most frequently activated signal
transduction cascades in human cancer. This family of lipid kinases plays a major regulatory role in
several biological processes, including proliferation, survival, apoptosis, differentiation, migration
and metabolism [76]. These numerous functions are served by distinct PI3K isoforms, which can
be grouped into three classes according to their structure and substrate specificity. Class I PI3K,
consisting of heterodimers of a catalytic subunit p110 and a regulatory subunit p85, is the most
implicated in oncogenesis and is activated by growth factors through G protein-coupled receptors
(GPCRs) and tyrosine kinase receptors (RTKs) [77]. PI3Ks phosphorylate phosphatidyl-inositol (4, 5)
P2 (PIP2) to phosphatidyl-inositol (3, 4, 5) P3 (PIP3), a second messenger allowing the recruitment and
activation of downstream effectors, such as phosphoinositide-dependent kinase 1 (PDK1) and AKT,
via pleckstrin homology (PH) domain-mediated docking. The serine-threonine protein kinase AKT
phosphorylates a wide range of cellular targets, including Mouse double minute 2 homolog (MDM2),
Glycogen synthase kinase 3 beta (GSK-3β), Forkhead box protein O1 (FOXO1), Bcl-2-associated
death promoter (Bad), Tuberous Sclerosis Complex 2 (TSC2)/tuberin and Caspase-9, and indirectly
activates mechanistic target of rapamycin (mTOR) and nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB), generating an overall anti-apoptotic effect and proliferative signal [78,79].
Importantly, the phosphatase and tensin homolog (PTEN) tumor suppressor negatively regulates
PI3K/AKT/mTOR signaling by dephosphorylating PIP3. In normal T-cells, PI3K/AKT cascade is
a common effector pathway downstream of NOTCH, IL-7 and pre-TCR signaling, allowing their
proper integration during early development and promoting survival of DN3 cells [80]. Indeed,
different knock-out models resulting in defective signaling display a block in T-cell differentiation at
Int. J. Mol. Sci. 2017, 18, 1904 7 of 29
the β-selection stage [81,82]. Moreover, the TCR and the co-stimulatory molecule CD28 signal through
PI3K/AKT to promote survival, proliferation and cytokine production in activated T-cells [83,84].
In T-ALL, PI3K/AKT pathway is commonly constitutively activated [85,86], mainly as a result
of the inactivation of PTEN, a lipid phosphatase functioning as the main negative regulator of PI3K
pathway [85,87]. In primary T-ALL samples, PTEN deletions or loss-of-function mutations have
been identified to cluster in exon 7, causing protein truncation at the carboxyl-terminus and its
consequent degradation [85,86,88–90]. Less frequently, aberrant hyperactivation of the pathway due
to gain-of-function mutations in PI3K regulatory (p85) and catalytic subunits (p110) (4, 5% of T-ALL
cases) or in AKT (2, 3% cases) have also been reported [86]. However, genetic alterations are not
sufficient to account for the very high frequency of PI3K signaling hyperactivation in T-ALL [87].
Indeed, non-genetic mechanisms, such as casein kinase 2 (CK2)-mediated phosphorylation and
reactive oxygen species (ROS)-induced oxidation, can contribute to PTEN inactivation, affecting
its lipid phosphatase activity [87]. Interestingly, normal and malignant thymocytes rapidly activate
the PI3K/AKT/mTOR signaling pathway in response to IL-7 stimulation [91,92]. Thus, IL-7R activating
mutations serve as an alternative mode of inducing enhanced PI3K/AKT/mTOR signaling in T-ALL
cells. Moreover, NOTCH1 mediated transcriptional upregulation of IL-7Rα [93] and HES1-mediated
transcriptional repression of PTEN [85] further contribute to enhance PI3K/AKT/mTOR signaling
in NOTCH1 dependent T-ALL. A further level of complexity is added by the findings that PTEN
mRNA can be targeted by miR-19 [94] or c-MYC [95] and that NOTCH1 likely regulates the dynamic
exchanges of regulatory B subunits of protein phosphatase 2A (PP2A) leading to a decreased affinity
of this phosphatase for critical targets such as phosphorylated AKT [96].
Moreover, insulin-like growth factors (IGFs) 1 and 2 bind to IGF1R, initiating a signaling cascade
including PI3K/AKT and RAS/rapidly accelerated fibrosarcoma (RAF)/mitogen activated protein
kinase (RAS/RAF/MAPK) (reviewed in [97]). IGF1R expression can be directly regulated by NOTCH1
and is important for T-ALL proliferation and leukemia initiating activity in vivo [66]. Additionally,
IGF1R is a target of miR-223 and NOTCH1 can regulate IGF1R, at least in part by repressing
miR-223 [98]. Moreover, long non-coding RNAs (lncRNA) such as LUNAR1 may contribute to
NOTCH1 dependent IGF1R upregulation and signaling [99].
Given the widespread constitutive activation of PI3K/AKT/mTOR signaling, this signaling
cascade has been explored as a novel therapeutic target in T-ALL. Experience with mTOR inhibition
in T-ALL is limited, although recent data implicate mTOR activation in the development of early T
progenitors and T-ALL [100]. In a mouse model of T-ALL evoked by Kras activation, Raptor deficiency,
an essential component of mammalian target of rapamycin complex 1 (mTORC1), dramatically
inhibited the cell cycle progression in oncogenic Kras-expressing T-cell progenitors, and specifically
prevented the development of T-ALL [100]. On the other hand, mTORC1 inhibition by rapamycin
prolonged survival of T-ALL bearing mice, but in the long run rapamycin-insensitive leukemia cells
emerged leading to disease progression [100]. In addition, rapamycin may modulate glucocorticoid
resistance, an important indicator of therapeutic failure in T-ALL [101]. However, through feedforward
loops between mTOR, PI3K and AKT, inhibition of mTOR often leads to hyperactivation of AKT
signaling [102]. This has spurred the search for other targets to hit therapeutically. At the level of PI3Ks,
several pan-PI3K class I inhibitors (LY924002 and NVP-BKM120) showed anti-leukemic effects in
T-ALL cell lines and primary patient samples having hyperactivation of PI3K/AKT pathway [103,104].
However, since only PI3Kδ and γ subunits are instrumental for T-cells, these constitute attractive
targets to increase specificity and reduce toxicity. Elegant work demonstrated that the PI3Kδ and PI3Kγ
isoforms are critically required to allow T-ALL development in a Pten-deficient mouse model [105].
In addition, the PI3Kδ/γ-specific inhibitor CAL-130 confirmed the “addiction” of Ptennull T-ALL on
PI3Kδ and PI3Kγ by prolonging survival of Pten null mice. Similar efficacy was seen in PTEN-deficient
primary human T-ALL samples [105]. Direct inhibition of AKT by the allosteric inhibitor MK-2206
has cytotoxic activity in some T-ALL cell lines and primary samples and may also target a putative
leukemia-initiating cell (LIC) population [106]. Additionally, AKT inhibition sensitizes T-ALL cells
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to glucocorticoids [107]. To circumvent the possible issue of drug resistance seen with individual
drug administration and problems related to feedforward loops, dual PI3K/mTOR inhibitors have
been developed. In T-ALL cell lines and primary T-ALL cells, PI-103 showed promising cytotoxic
effects [108,109]. Interestingly, the dual PI3K/mTOR inhibitor PI-103 determined upregulation of
NOTCH1 target genes, including c-MYC. Accordingly, the combination of PI-103 with either a gamma
secretase inhibitor (GSI) (such as L-685) or a c-MYC inhibitor (10058-F4) enhanced the effectiveness of
PI-103. Given the overall convincing preclinical data on PI3K/AKT/mTOR signaling in T-ALL, but
rather disappointing results of clinical trials [110], probably rational strategies of combination therapy
will be needed.
5.3. IL-7R/JAK/STAT Pathway
Interleukin 7 (IL-7) is an essential cytokine for normal T-cell development and homeostasis that
promotes cell survival and cell cycle progression. Upon ligand binding, the IL-7 receptor-α chain
(IL-7Rα; CD127) and the common γ chain (γc; CD132) dimerize and induce the transphosphorylation
of JAK3 and JAK1. Activated JAKs phosphorylate the cytoplasmic tail of the receptor allowing the
recruitment and phosphorylation of STAT5 (signal transducer and activator of transcription 5), which
in turn dimerizes and translocates into the nucleus to regulate the transcription of target genes such
as B-cell CLL/lymphoma2 (BCL-2) family members [111]. Besides JAK/STAT pathway, IL-7 can also
mediate anti-apoptotic and proliferative signals via PI3K/AKT (Section 5.2) and RAS/MAPK pathways
(Section 5.4). The expression of IL-7R is strictly regulated, as IL-7 is crucial at different stages of T-cell
development for survival and maturation of specific cellular subsets in the thymus, as well as for the
homeostasis of mature naïve and memory T-cells in the periphery (reviewed in [112,113]). Indeed,
defective signaling in IL-7−/− or IL-7R−/− knock out mice results in early thymic development arrest
and lymphopenia [114–116], while in humans inactivating mutations in the IL-7Rα [116] or γc [117]
cause severe combined immunodeficiency.
Along with the pivotal role in T-cell biology, IL-7/IL-7R pathway has been also shown to promote
leukemogenesis in vivo, since T- and B-cell lymphomas develop in IL-7 transgenic mice [118,119].
Analogously to normal T lymphocytes, T-ALL cells express IL-7R and stromal cells in the thymus and
in the bone marrow—the microenvironments where T-ALL arises- secrete IL-7. Several studies have
demonstrated that IL-7 can favor disease progression both in vitro and in vivo [120–123], regulating
cell viability and proliferation. In T-ALL blasts, but not in healthy lymphocytes, IL-7 promotes cell cycle
entry and cell viability, through the down-regulation of p27kip1 and up-regulation of BCL2 [91,124]
in a PI3K/AKT-dependent manner [91,125]. Activating mutations in IL-7Rα have been identified in
approximately 10% of T-ALL patients, most frequently leading to the introduction of a cysteine residue
which allows ligand-independent homodimerization of the receptor and consequent constitutive
signaling [126,127]. These mutations were found mainly within the TLX1/3, HOXA positive and
ETP-ALL genetic subgroups [41,42]. Gain-of-function mutations in JAK3 and JAK1 [42,128,129], as well
as in STAT5 gene [130,131] have been detected in a variable fraction of T-ALL patients, along with a
rare t(9;12)(p24;p13) translocation driving the expression of a constitutively active fusion protein
ETV6-JAK2 [132,133]. It is also of relevance that inactivation of the gene that encodes PTPN2
has been observed in 6% of T-ALL cases, and results in enhanced JAK1/STAT5 signaling upon
IL-7 stimulation [134,135]. Interestingly, IL-7R signaling cascade can be hyperphosphorylated in
patients who do not carry genetic aberrations in the IL-7R, JAK, or STAT5 genes, suggesting that
additional mechanisms exist to activate this pathway [136,137]. Coherently, recurrent loss-of-function
mutations in the dynamin 2 (DNM2) gene were found to impair clathrin-dependent endocytosis of
IL-7R leading to increased surface expression and enhanced IL-7R signaling in T-ALL cells. Thus,
genetic evidence combined with transcriptional regulation of IL-7R by activated NOTCH signaling [93]
and/or zinc finger E-box-binding homeobox 2 locus (ZEB2) overexpression [137], makes this signaling
pathway highly attractive from a therapeutic stand point. Indeed, JAK inhibitors (ruxolitinib
and tofacitinib) used in patients with rheumatoid arthritis [138] and myelofibrosis [139] could be
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repurposed for the treatment of T-ALL cases with documented activation of the IL-7R/JAK/STAT
pathway. Thus, in the context of T-ALL pharmacological inhibition of JAK1/JAK2 by ruxolitinib has
shown therapeutic activity in ETP-ALL primary patient xenografts in vivo in both the presence and
the absence of JAK-STAT mutations [140]. Incidentally, the group headed by Meijerink found that
mutations in the IL-7R signaling pathway (including JAK1 and KRAS mutations) were associated
with glucocorticoid resistance in patient samples, and that inhibition of Mitogen-activated protein
kinase kinase/extracellular signal–regulated kinases (MEK/ERK) or PI3K/AKT/mTOR pathways
enhanced steroid sensitivity in primary samples [141]. Surprisingly, the JAK1 inhibitor ruxolitinib had
synergistic cytotoxic effects only in a minority of primary T-ALL samples, possibly due to the low
proliferative capacity of primary T-ALL cells in vitro [141].
5.4. RAS Pathway
RAS proteins, including the isoforms Harvey rat sarcoma viral oncogene homolog (H-RAS),
Neuroblastoma RAS viral oncogene homolog (N-RAS) and Kirsten rat sarcoma viral oncogene homolog
(K-RAS), are small GTPases acting as molecular switches that oscillate between an inactive GDP-loaded
and an active GTP-loaded conformation. RAS proteins transduce the signal from multiple cell surface
receptors including the TCR, RTKs and cytokine receptors, to downstream effector pathways, such
as the PI3K/AKT and MAPK pathways, to regulate a number of cell fate decisions. RAS genes are
mutated in about one third of human cancers, with mutations in N-RAS being the most prevalent in
hematological malignancies. Approximately 15% of all hematological tumors display point mutations
in codons 12, 13 or 61 of RAS genes, impairing its GTPase function and leading to a constitutively
active form of the protein [142]. Mutations in N-RAS and K-RAS are enriched in relapsed ALL patients
and appear to be associated with steroid resistance [143,144]. Moreover, K-RAS mutations rendered
lymphoblasts resistant toward methotrexate, while sensitizing them to vincristine [144]. Importantly,
a conditional K-RasG12D (where Glycine in codon 12 is mutated to Aspartic acid in K-Ras) knock-in
mouse model develops T-cell leukemia/lymphoma [145] and Ras activating mutations cooperate
with NOTCH1 mutations to drive T-ALL development [146]. Moreover, RAS signaling is frequently
hyperactivated in T-ALL patients [147], either by mutations in RAS itself [144,148–150] -especially in
the early precursor subtype- [42] or by alterations in the activity or expression of other regulatory
components of the pathway, mainly RAS GEFs (RAS guanidine nucleotide exchange factors) and
RAS GAPs (RAS GTPase activating proteins). Indeed, neurofibromin 1 (NF1), a tumor suppressor
protein enhancing RAS hydrolyzing activity, was reported to be mutated in T-ALL patients [151],
as well as to have a leukemogenic potential in vivo when deleted in combination with p120-RAS GAP
in T-cells [152]. Another peculiar mechanism of increased RAS signaling in T-ALL results from the
overexpression of RAS guanine nucleotide-releasing protein 1 (RASGRP1), a RAS GEF normally highly
expressed in T-cells and critical for thymocyte differentiation and signal transduction downstream
of the TCR [153]. In T-ALL, RASGRP1 induces higher rates of GTP/GDP exchange and promotes
cytokine-induced RAS downstream signaling, mainly via the PI3K/AKT axis [154,155]. Moreover,
loss-of-function mutations in PTPN11, encoding the protein phosphatase non-receptor type 11, which
negatively regulates the RAS pathway, have also been described [156].
5.5. ABL Kinase
ABL1 gene encodes a ubiquitously expressed tyrosine kinase and it is found to be rearranged in
8% of T-ALL cases [157]. The resulting fused protein products display constitutive kinase activity and
promote survival and proliferation pathways. While B-cell receptor (BCR)-ABL1 fusion protein
following the Philadelphia translocation t (9; 22) (q34; q11.2) is a hallmark of chronic myeloid
leukemia and is also common in precursor B-cell ALL (B-ALL) [158], BCR-ABL1-positive T-ALL
patients are exceptionally rare [159]. The most frequent and T-ALL-specific ABL1 rearrangement
is NUP214-ABL1 episomal amplification (6% cases), which was described in T-ALL cell lines, as
well as in adult and pediatric patients associated with TLX1 or TLX3 expression and CDKN2A
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deletion [32,160,161]. Other less common partners of ABL1 that were sporadically reported in
T-ALL also include ETV6 [162] and echinoderm microtubule-associated protein EML1 [163]. All the
above-mentioned ABL1 fusion proteins render cells sensitive to small tyrosine kinase inhibitors such
as imatinib mesylate (Glivec) [164,165]; however, the onset of resistance due to acquired mutations in
ABL1 gene has been observed [166].
5.6. NF-κB Pathway
Nuclear factor kappa B subunit (NF-κB) family of transcription factors includes five members,
p50 (NF-κB1), p52 (NF-κB2), v-Rel avian reticuloendotheliosis viral oncogene homolog A (RelA
or p65), v-Rel avian reticuloendotheliosis viral oncogene homolog B (RelB) and v-Rel avian
reticuloendotheliosis viral oncogene homolog (c-Rel), which all contain a Rel homology domain
(RHD) and form homo- and heterodimers with different transcriptional properties. In the resting
state, inactive NF-κB dimers are retained in the cytoplasm by inhibitor of nuclear factor kappa B (IkB)
proteins. Upon stimulation, IkB kinase (IKK) complex phosphorylates IkB targeting it for proteosomal
degradation, thus allowing NF-κB dimers to translocate to nucleus and bind DNA. Depending on the
initiating stimulus and the effector dimers that are activated, a canonical and a non-canonical pathway
can be distinguished. NF-κB signaling exerts a pivotal regulatory role in innate and acquired immune
responses and its alteration has been associated to inflammatory diseases and immune-deficiencies,
as well as to solid and hematological tumors [167]. In T-cells, NF-κB signaling can be activated
by a variety of immune signals, including antigens, Toll-like receptor ligands and inflammatory
cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin 1β [168]. NF-κB was reported
to be involved not only in early thymocyte development, promoting a pre-TCR-induced survival
step between DN3 and DN4 stages [169], but also in antigen-dependent T-cell selection, lineage
commitment and maturation. Indeed, different levels of NF-κB can regulate CD8+, but not CD4+,
positive and negative selections [170]. Moreover, NF-κB signaling is also required for thymic Treg
development [171,172] and IFN-γ-producing NKT cell maturation [173,174]. Unlike other lymphoid
malignancies, mutations in NF-κB signaling genes are rare in T-ALL, however constitutive activation
of the pathway has been observed in T-ALL primary samples [175,176]. NOTCH1, which is mutated
in half of T-ALL cases (see Section 5.1), can activate NF-κB pathway in T-ALL cell lines and in the
intracellular NOTCH1 (ICN1)-induced mouse model, either transcriptionally, promoting RelB and
p52 expression, or indirectly via IKK complex activation [177]. Moreover, NOTCH1 target HES1 was
reported to repress cylindromatosis (CYLD), a deubiquitinase negatively regulating IKK complex, both
in primary T-ALL samples and cell lines [178]. The critical role of this interaction is demonstrated by
the anti-leukemic effects of NF-κB inhibition in T-ALL and the strict requirement of NF-κB signaling
for NOTCH1-induced transformation. Besides NOTCH1, in vivo constitutive activation of NF-κB
was also reported in ETV6-JAK2 [179], Tal1 [180] and NOTCH3 mouse models of T-ALL [181]. Other
reports highlighted a pro-oncogenic role of NF-κB in T-ALL leukemogenesis by contributing to the
crosstalk between leukemic T-cells and microenvironmental stromal cells [179,182]. Thus, NF-κB
appears as an appealing target for T-ALL treatment. However, moderate results have been obtained
in T-ALL, as demonstrated by modest increases in sensitivity to apoptosis of T-ALL cell lines treated
with IKK inhibitors [177,178] or the proteasome inhibitor bortezomib [177]. The therapeutic value
of NF-κB inhibition was also investigated in relapsed pediatric T-ALL patients, where treatment with
bortezomib in combination with multiagent chemotherapy was shown to be more effective than
single treatments [183].
5.7. Hedgehog Pathway
Hedgehog (HH) signaling is a conserved pathway essential for stem cell biology during embryonic
development and tissue homeostasis and repair in adult life [184]. The canonical pathway can
be activated by binding of different secreted ligands (Sonic Hedgehog, SHH; Desert Hedgehog,
DHH; Indian Hedgehog, IHH) to transmembrane receptors Patched (PTCH1 or PTCH2). Patched is
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an unusual receptor because it is a tonic repressor of another transmembrane receptor, Smoothened
(SMO). Thus, once Patched interacts with hedgehog ligands, SMO is activated. Activated SMO
transduces the signal to Gli family of transcription factors (GLI1, GLI2, and GLI3), resulting in their
nuclear translocation. GLI1 and GLI2 mostly act as transcriptional activators, while GLI3 as
a repressor [184]. Besides a role, though controversial, in primitive and definitive hematopoiesis [185],
HH also regulates early stages of thymic development, especially at the DN1-DN2 and DN-DP
transition [186–188]. Indeed, immature T-cells moving across the thymus are exposed to different
concentrations of stroma-secreted HH ligands, resulting in variable levels of pathway activation and
specific patterns of expression of GLI genes and their targets [187,189,190].
HH signaling is aberrantly activated by oncogenic mutations or autocrine/paracrine/inverse
paracrine mechanisms in a variety of solid and hematological malignancies, including acute and chronic
myeloid leukemia and multiple myeloma, contributing to tumor development and expansion [191,192],
as well as cancer stem cell maintenance [193–195]. In the context of T-ALL, evidence of the involvement
of Hedgehog signaling is emerging. Recent studies showed that pathway components are expressed
and signaling is active in some T-ALL cell lines and primary samples [196,197]. In addition, rare somatic
mutations in HH pathway members were found in T-ALL, including two truncating mutations in SMO
(R726 * and R763 *) and missense mutations in GLI1 (S538F) and GLI3 (G727R) [198]. Additionally,
the same group reported that the HH cascade was active in ≈20% of the patient samples, through
ectopic expression of SHH and IHH and of the downstream GLI1 transcription factor, suggesting
that the crosstalk with other pathways such as IL-7, vascular endothelial growth factor (VEGF)
or NOTCH signaling pathways and the overall transcriptional deregulation intrinsic to T-ALL,
rather than pathway-intrinsic mutational events, are responsible for this activation [197]. Moreover,
ectopic expression of HH ligand in JAK3 (M511L) mutant mouse model of T-ALL induces a growth
advantage, higher infiltration rates, and thymic epithelial cell activation indicating a supportive
role in leukemia development. However, Gao et al. found HH signaling to be dispensable for
NOTCH-induced leukemia induction and progression [196]. The debated effects of Smo deficiency
in normal hematopoiesis [199] and leukemogenesis [196], together with the reduced efficacy of SMO
inhibitors (cyclopamine and GDC-0449) on cell line growth with respect to GLI1 inhibitors [197,200],
underscores the importance of non-canonical Smo-independent modulation of HH signaling and the
necessity of dissecting the complex regulatory network upstream of GLI1 [201]. Indeed, amounting
evidence indicate that ligand-independent hedgehog signaling, also named non-canonical hedgehog
signaling, not sensitive to SMO inhibitors plays an essential role in cancer [202]. Thus, given the modest
activity of the FDA-approved SMO inhibitors against xenografts of human T-ALL and the known
issue of emergence of resistance to these drugs in other cancer clinical trials, it will be imperative
to determine which signaling pathways alter sensitivity to HH pathway inhibitors. These findings will
be crucial to design rational combination therapies incorporating HH pathway inhibitors in T-ALL.
5.8. Calcineurin/NFAT Pathway
Calcineurin (Cn) is a calcium-dependent serine/threonine phosphatase composed of a catalytic
subunit (PPP3CA or CnA) and a regulatory subunit (PPP3CB or CnB), implicated in a variety
of physiological and developmental processes in nervous, cardiovascular, musculoskeletal and immune
system [203]. Upon surface receptor stimulation, increased levels of intracellular calcium are detected
by sensor protein calmodulin, which in turn enhances calcium-induced Cn activation. Calcineurin
dephosphorylates a number of substrates, prominently NFAT family members, allowing their nuclear
translocation and transcriptional activity. In normal T-cells, the cooperation between NFAT factors with
different transcriptional partners leads to the expression of distinct set of genes, including inflammatory
cytokines, thus eliciting multiple effects [204]. Cn/NFAT pathway is known to induce cytokine
gene expression in activated T-cells upon TCR engagement and its essential function is underscored
by the use of calcineurin inhibitors such as cyclosporine (CsA) and FK506 as immunesuppressor
drugs in transplantation medicine [79]. A role for NFAT members has also been described in
Int. J. Mol. Sci. 2017, 18, 1904 12 of 29
positive selection during thymocyte development, as demonstrated by CnAβ−/− and CnB−/−
conditional knock-out models [205,206], in T helper cell (TH) TH1 versus TH2 differentiation [207]
and in the induction of anergy [208].
Thus, the Cn/NFAT signaling pathway is implicated in numerous biologically relevant processes,
connecting perturbations in calcium signaling to gene expression. Recently, this signaling pathway
has been implicated in the induction and progression of hematological malignancies [209]. In fact,
nuclear NFAT2 was found in cases of Burkitt’s lymphoma, diffuse large B cell lymphoma and
aggressive T-cell lymphoma [210,211]. Surprisingly, in fibroblasts, distinct and opposing roles for the
transcription factors NFAT1 and NFAT2 in tumorigenesis were revealed in which NFAT1 functions
as a tumor suppressor and NFAT2 as an oncogene [212]. In T-ALL, Cn was reported to contribute
to leukemogenesis in ICN1 and ETV6-JAK2 mouse models of T-ALL, in which sustained activation of
the pathway by microenvironmental cues leads to constitutive desphosphorylation of NFAT. Inhibition
of Cn by CsA and FK506 could induce significant anti-leukemic effects leading to rapid disease
remission and improved survival. On the other hand, ectopic expression of a constitutively active
Cn mutant accelerated leukemia progression and invasiveness [213]. The molecular mechanisms
that account for sustained activation of Cn in leukemic cells remain to be identified, but may require
signaling from the in vivo tumor microenvironment and have been shown to be independent of TCR
and pre-TCR expression (the main Cn activators in normal T progenitors), at least in the ETV6-JAK2
mouse model [213]. Recent developments have further strengthened the role of Cn activation in
the pathogenesis of T-ALL. Indeed, elegant work demonstrated that conditional deletion of CnB1
in leukemic cells impairs leukemia propagation, reduced survival and homing upsetting adhesive
interactions between leukemic cells and their supportive stroma [214]. In addition, Cn activation was
found to be critical for leukemia initiating/propagating cell activity as Cn-deficient leukemic cells
were unable to transplant the disease to syngeneic recipient mice [214]. A limitation of the therapeutic
pre-clinical findings is that currently available Cn inhibitors appear suboptimal as therapeutic agents,
since they are associated with serious side effects [215], show off-target effects in T-ALL cells [214],
and potentially interfere with the anti-tumor immune response. Thus, it is not surprising that
alternative options have been explored to dampen Cn signaling. In fact, several groups have tried
to identify and target molecular pathways acting downstream of Cn and critical in T-ALL biology.
Stemming from this consideration, recent work identified a series of Cn-dependent genes in T-ALL
including cell cycle inhibitors (notoriously difficult to target therapeutically), and genes implicated in
adhesion/migration [214]. The authors followed-up on these findings and found that Cn regulates
the adhesive/migratory properties of T-ALL cells by increasing C-X-C motif chemokine receptor 4
(CXCR4) surface expression in a cortactin-dependent way [216]. The ligand for this chemokine receptor,
C-X-C motif chemokine ligand 12 (CXCL12) or stromal-derived growth factor-1 (SDF-1) is of particular
importance as it is secreted by numerous cell types in the bone marrow such as osteoblasts lining
the bone endosteum and endothelial cells [217] and is implicated in the homing of hematopoietic
stem cells to the bone marrow [218]. Recent studies have demonstrated that the critical source of
CXCL12 is the endothelial compartment of the vascular niche [219]. Inactivation of CXCL12 in the
vascular niche or CXCR4 in T-ALL cells impairs their LIC activity in both murine T-ALL and human
xenografts [216,219]. Of note, another CXCL12 binding receptor has been identified and called C-X-C
motif chemokine 7 (CXCR7) [220,221], whose relevance to T-ALL biology is still ill-defined. In fact,
T-ALL cells express CXCR7 and it may potentiate CXCR4 responses to CXCL12 [222]. Recently, we
undertook a more proteomic approach to identify putative downstream targets/effectors contributing
to the pro-oncogenic activity of Cn in T-ALL. Indeed, we used tandem affinity chromatography
followed by mass spectrometry to identify Cn-interacting proteins in T-ALL cells. We found that the
isolated proteins were implicated in numerous key signaling pathways, including eukaryotic initiation
factor 2 (eIF2) signaling, cell cycle control, mTOR signaling and 14-3-3 mediated signaling [223].
Systematic inhibition of the top signaling pathways enriched in our CnA protein complex identified
a highly synergistic drug interaction between inhibition of Cn and the PI3K/AKT/mTOR signaling
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pathway. Further studies showed that AKT represented the critical node of the pathway to inhibit
to obtain the most synergistic cytotoxic effect with Cn inhibitors. This cytotoxic effect was prevalently
due to the strong reduction in the expression of the anti-apoptotic protein myeloid leukemia 1 (MCL-1).
Our studies also uncovered a complex interaction between GSK-3β and Cn/NFAT signaling in T-ALL
cells [224]. In fact, in resting cells Glycogen Synthase Kinase 3 (GSK-3) participates in maintaining NFAT
proteins in their inactive hyper-phosphorylated form, antagonizing Cn/NFAT signaling [225,226].
GSK3 is a constitutively active kinase that is phosphorylated and inactived by PI3K and AKT
signaling [227]. Surprisingly, we found that CnA was able to directly interact with GSK-3β and
increase its kinase activity possibly by augmenting its autophosphorylation. These results reiterate
the complex role of GSK-3 in cancer, as this kinase has been shown to act as a tumor suppressor in
certain tumors, whereas in others it acts a tumor promoter [228]. We found that GSK-3β acts mainly
as a tumor promoter in T-ALL by promoting the stabilization of proteins such as MCL-1, c-MYB, and
possibly X-linked inhibitor of apoptosis (XIAP). Interestingly, dual Cn and GSK-3β inhibition showed
a synergistic anti-leukemic effect in vitro and in vivo, via downregulation of anti-apoptotic proteins
such as XIAP and claspin [224]. In conclusion, all these studies highlight how the Cn/NFAT pathway
links microenvironmental derived signals with the intrinsically altered signaling pathways found in
T-ALL and provide additional targets and perspectives for future therapeutic strategies.
5.9. Wnt Signaling
Wnt signaling plays an important role in normal hematopoiesis [229,230], and it often becomes
de-regulated in malignancies of the hematological system [231]. Briefly, the Wnt signaling cascade is
often discerned into canonical or Wnt/β-catenin pathways and the non-canonical pathways. In the
canonical Wnt pathway, in the absence of Wnt ligands, cytoplasmic levels of β-catenin are kept very
low due to its constitutively phosphorylation and degradation through the action of a protein complex.
This so called destruction complex is composed of two negative regulatory kinases, GSK3β and
casein kinase 1 (CK1), and at least two anchor proteins, Axin1 or Axin2 and adenomatous polyposis
coli (APC) protein. APC and Axin sequester β-catenin in the cytoplasm. Upon binding of Wnt
ligands to the Frizzled receptor and LDL receptor related protein 6 (LRP6), the destruction complex
is inactivated, allowing the accumulation of dephosphorylated β-catenin and its migration to the
nucleus where it binds members of the T-cell factor (TCF)/Lymphoid enhancer binding factor (LEF)
transcription factor family and activates the transcription of Wnt-responsive genes [232]. It is very
likely that both the microenvironment (thymus) and the cell of origin of leukemia (immature T-cell)
will greatly influence how normal Wnt signaling in these cells is deregulated and may subsequently
lead to malignant transformation [233]. Thus, the interplay between microenvironmental signals, such
as Wnt ligands and antagonists in combination with the expression of intracellular components, such
as TCF/LEF transcription factors and intracellular inhibitors (such as β-catenin interacting protein,
ICAT), in the progenitor cells themselves will influence how the normally tightly regulated Wnt
signaling levels may predispose to malignant transformation. Signaling pathways and oncogenes
aberrantly expressed may also influence Wnt signaling, helping to tip the balance. Deregulation of Wnt
signaling is a frequent event in cancer, however its role in the pathogenesis of T-ALL has only recently
been unveiled. In the study by Guo et al. [234], a constitutively active form of β-catenin was used
that was expressed from the DN3 stage onwards and determined the accumulation of DP thymocytes
which were predisposed to malignant transformation. The resulting leukemias were associated with
c-MYC upregulation but did not develop NOTCH1 mutations. These findings, together with the report
that human T-ALL cases without NOTCH1 mutations show high Wnt signaling levels [235], suggest
that aberrant Wnt signaling may be a leukemia initiating event similar to NOTCH signaling. On the
other hand, two recent studies show an important tumor suppressor role for T-cell factor 1 (TCF1) in
T-ALL development [236,237]. In both studies, mice deficient for Tcf1 are highly susceptible to develop
phenotypically heterogeneous leukemias (due to several incomplete successive T-cell developmental
blocks). In fact, it was found that upon Tcf1 deletion, LEF1 protein levels become deregulated in all
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thymic subsets, resulting in abnormally high levels of the long isoform of LEF1, thus predisposing
thymocytes to leukemic transformation. Interestingly, a key role for LEF1 has been found in mouse
models of leukemias induced by activated forms of NOTCH [238]. In fact in these lymphomas,
NOTCH1 was found to directly transcriptionally regulate LEF1 expression. Hence, deregulation of
LEF1 expression, either via lack of the tumor suppressor TCF1 or aberrant activation of NOTCH
pathway accelerates lymphomagenesis. These findings in the mouse appear relevant for human T-ALL.
In fact deletions and mutations in LEF1 that inactivate its expression has been found in T-ALL [239],
and more recently loss of TCF1 has been reported in a subset of pediatric T-ALL, the ETP subgroup, in
which two patients were found to have deletions of Transcription factor 7 (TCF7) [the gene encoding
TCF1] [237]. Additionally, gene expression profiling of Tcf7−/− lymphomas showed upregulated
expression of myocyte enhancer factor 2c (Mef2c) [236], which has been recently associated with an
immature T-ALL subgroup [26]. In conclusion, these results indicate that TCF1 may act as a tumor
suppressor in certain subgroups of pediatric T-ALL (ETP-ALL and MEF2C positive T-ALL). Recently,
a further twist to the role of Wnt signaling has been added. In fact, active Wnt signaling has been
shown to be restricted to minor subpopulations within bulk tumors, and these Wnt-active subsets
were highly enriched for leukemia initiating activity (i.e., putative T-ALL stem cells) [240]. In these
stem cells, hypoxia-inducible factor α (HIF-1α) was also activated. Genetic inactivation of β-catenin or
HIF-1α severely reduced stem cell frequency, while having minimal impact on the growth or viability
of bulk tumor cells, implying that elements of Wnt and Hif pathways specifically support leukemic
stem cells.
5.10. Altered Metabolic Homeostasis
Metabolic homeostasis is a fundamental trait of cells which becomes altered in cancer
in order to satisfy the heightened demand for metabolites necessary for growth and proliferation.
Oncogenic mutations can directly alter cellular metabolism in a cell-intrinsic way, favoring malignant
transformation. Moreover, microenvironmental cues such as hypoxia, nutrient availability, oxidative
stress and cross-talk from neighboring cells all affect cancer cell metabolism and contribute to determine
metabolic heterogeneity within the tumor [241]. It is thus becoming clear that the metabolic phenotype
of cells within tumors is heterogeneous (some cells within the tumor are predominantly glycolytic,
whereas others have primarily a oxidative phosphorylation (OXPHOS) metabolic phenotype) also due
to the metabolic milieu of the tumor microenvironment. Leukemia is no exception as these cells often
expand in hypoxic areas such as the bone marrow or the thymus [242,243]. Moreover, in T-ALL many
of the metabolic regulators that allow metabolic adaptation such as PI3K/AKT/mTOR, NOTCH1,
c-MYC, AMPK, and HIF-1 are frequently deregulated, leading these cells to exhibit increased glucose
consumption and increased glycolysis [244]. T-ALL cells are also highly dependent on glutamine, as
this metabolite can be used to produce glutathione, amino acids, hexosamine (amino sugars involved
in the synthesis of glycosylated molecules), nucleotides, and fuel mitochondrial Krebs cycle through
the production of α-ketoglutarate thus allowing the synthesis of pyruvate, NADPH, acetyl-CoA, or
citrate [241]. A key regulator of glutamine metabolism (glutaminolysis) is the transcription factor MYC.
Indeed, this oncogenic transcription factor regulates factors implicated in glutaminolysis and glutamine
uptake such as glutamine transporters (MCT1) and glutaminase [245]. MYC is often de-regulated
in T-ALL (see Section 5.1) as a consequence of its transcriptional activation by NOTCH1, and coherently
supports NOTCH1 induced transformation. Recently, using a NOTCH1-dependent mouse model
of T-ALL, inhibition of NOTCH1 signaling through the use of GSI attenuated glutaminolysis, rendering
cells dependent on autophagy to support metabolism and survival [58]. Moreover, glutaminase
inhibition synergized with NOTCH1 inhibition to inhibit leukemia growth. Significantly, PTEN
deletion, rendered T-ALL cells resistant to gamma secretase inhibition by upregulating glycolysis [58].
Recent evidence suggests that AMPK confers cancer cells with the ability to cope with metabolic
stresses by regulating glucose metabolism. AMPK is a heterotrimeric serine/threonine kinase
composed of an α-catalytic subunit and two regulatory subunits β and γ which regulate its activation
Int. J. Mol. Sci. 2017, 18, 1904 15 of 29
and substrate specificity [246]. AMPK is a cellular fuel sensor, activated under conditions of ATP
depletion and elevated AMP levels such as nutrient depletion, hypoxia and other metabolic or
environmental stresses [247,248]. Activation of AMPK by falling energy status, promotes metabolic
homeostasis by activating ATP-generating pathways such as glucose uptake, glycolysis, fatty
acid uptake and oxidation, and mitochondrial biogenesis on the one hand and by inactivating
ATP-consuming processes such as fatty acid, cholesterol and protein synthesis. In cancer cells,
activation of AMPK can also suppress proliferation and growth through multiple mechanisms,
including p53 activation, inhibition of mTORC1 pathway, or activating transcriptional responses [247].
Thus, the role of AMPK in cancer is not yet fully understood, as it seems to have both tumor suppressive
and promoting roles, depending on the cellular context. AMPK can thus have growth suppressive
functions in certain cancer settings [249] such as the Eµ-myc induced lymphoma model, in which
deletion of the α1 catalytic subunit of AMPK promoted lymphomagenesis. Further, pharmacological
activation of AMPK can slow the growth of some tumors such as breast cancer [250]. In hematological
malignancies such as T-ALL, AMPK has been shown to restrain tumor growth [94], and AMPK
activation (mainly using agonists like metformin or AICAR) suppresses leukemia cell growth through
inhibition of mTORC1 [251], p38 mitogen activated protein kinase (p38 MAPK) [252] or unfolded
protein response (UPR) signaling [253]. Conversely, multiple oncogenic signals, including RAS and
MYC, can generate metabolic stress [254,255] and AMPK may promote cancer cell survival under
these conditions. Indeed, AMPK may be important to mitigate metabolic stress in myeloid leukemia
initiating cells (LICs) [256] and activated T-cells in vivo [257]. In fact, in mouse models of acute
myeloid leukemia and chronic myeloid leukemia [256], deletion of the α1 catalytic subunit of AMPK
depleted LICs and prolonged leukemia free survival through reduced glucose uptake and glycolysis,
determining depletion of reducing agents such as NADPH and glutathione. This leads to increased
oxidative stress and DNA damage accumulation in LICs. Moreover, AMPK inhibition was found
to enhance apoptosis in MLL-rearranged pediatric B-ALL cells [258]. An elegant study recently
compared the metabolic programs of primary T-ALL and normal activated T-cells [259]. Surprisingly,
this study found that although T-ALL cells utilize aerobic glycolysis this usage is restrained compared
to normal proliferating T-cells [259]. Moreover, NOTCH1 overexpression induced metabolic stress
that led to AMPK activation that acted to restrain glycolysis through inhibition of mTORC1 and
promoted mitochondrial oxidative metabolism and mitochondrial Complex I activity to mitigate stress.
Thus, exacerbating this stress by AMPK or mitochondrial inhibition may provide a novel therapeutic
approach for T-ALL.
6. Conclusions
T-ALL is an aggressive hematological disease for which few therapeutic options are available in the
case of primary resistant or relapsed disease, highlighting the need for better risk stratification and the
necessity to identify more effective targeted therapies [4]. Although, in the past decades, huge progress
has been made in our understanding of the genetic landscape and molecular pathogenesis behind
T-ALL, some gaps in our knowledge are present. In fact, dissecting the intricate signaling networks
governing the interaction between environmental permissive cues and oncogenic cell-intrinsic factors
leading to metabolic homeostasis of leukemia cells will contribute to fully capture critical steps of
T-ALL pathogenesis. Thus, the wealth of information gained in the past decades on the role of
oncogenes and tumor suppressors, together with cutting-edge studies evaluating the genetic and
epigenetic landscape of T-ALL will need to be combined with a better understanding of the leukemic
“nich” to design effective targeted therapies for the treatment of T-ALL.
Acknowledgments: Funding support provided in part by Ministero dell’Istruzione, dell’Università e della Ricerca
(MIUR) Ex 60%, Progetto di Ricerca di Ateneo (PRAT; Università di Padova; CDA #152403), and Istituto Oncologico
Veneto 5 × 1000 fund (Progetto Sinergia tra Oncologia Molecolare e Clinica) to Erich Piovan.
Conflicts of Interest: The authors declare no conflict of interest.
Int. J. Mol. Sci. 2017, 18, 1904 16 of 29
References
1. Ferrando, A.A.; Neuberg, D.S.; Staunton, J.; Loh, M.L.; Huard, C.; Raimondi, S.C.; Behm, F.G.; Pui, C.H.;
Downing, J.R.; Gilliland, D.G.; et al. Gene expression signatures define novel oncogenic pathways in T cell
acute lymphoblastic leukemia. Cancer Cell 2002, 1, 75–87. [CrossRef]
2. Coustan-Smith, E.; Mullighan, C.G.; Onciu, M.; Behm, F.G.; Raimondi, S.C.; Pei, D.; Cheng, C.; Su, X.;
Rubnitz, J.E.; Basso, G.; et al. Early T-cell precursor leukaemia: A subtype of very high-risk acute
lymphoblastic leukaemia. Lancet Oncol. 2009, 10, 147–156. [CrossRef]
3. Inukai, T.; Kiyokawa, N.; Campana, D.; Coustan-Smith, E.; Kikuchi, A.; Kobayashi, M.; Takahashi, H.; Koh, K.;
Manabe, A.; Kumagai, M.; et al. Clinical significance of early T-cell precursor acute lymphoblastic leukaemia:
Results of the Tokyo children’s cancer study group study L99-15. Br. J. Haematol. 2012, 156, 358–365.
[CrossRef] [PubMed]
4. Pui, C.-H.; Robison, L.L.; Look, A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371, 1030–1043. [CrossRef]
5. Belver, L.; Ferrando, A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia.
Nat. Rev. Cancer 2016, 16, 494–507. [CrossRef] [PubMed]
6. Passaro, D.; Quang, C.T.; Ghysdael, J. Microenvironmental cues for T-cell acute lymphoblastic leukemia
development. Immunol. Rev. 2016, 271, 156–172. [CrossRef] [PubMed]
7. Weng, A.P.; Ferrando, A.A.; Lee, W.; Morris, J.P.; Silverman, L.B.; Sanchez-Irizarry, C.; Blacklow, S.C.;
Look, A.T.; Aster, J.C. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.
Science 2004, 306, 269–271. [CrossRef] [PubMed]
8. Hebert, J.; Cayuela, J.M.; Berkeley, J.; Sigaux, F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and
MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell
lineage acute lymphoblastic leukemias. Blood 1994, 84, 4038–4044. [PubMed]
9. Lind, E.F.; Prockop, S.E.; Porritt, H.E.; Petrie, H.T. Mapping precursor movement through the postnatal
thymus reveals specific microenvironments supporting defined stages of early lymphoid development.
J. Exp. Med. 2001, 194, 127–134. [CrossRef] [PubMed]
10. Grabstein, K.H.; Waldschmidt, T.J.; Finkelman, F.D.; Hess, B.W.; Alpert, A.R.; Boiani, N.E.; Namen, A.E.;
Morrissey, P.J. Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal
antibody. J. Exp. Med. 1993, 178, 257–264. [CrossRef] [PubMed]
11. Sudo, T.; Nishikawa, S.; Ohno, N.; Akiyama, N.; Tamakoshi, M.; Yoshida, H. Expression and function of the
interleukin 7 receptor in murine lymphocytes. Proc. Natl. Acad. Sci. USA 1993, 90, 9125–9129. [CrossRef]
[PubMed]
12. Rodewald, H.R.; Kretzschmar, K.; Swat, W.; Takeda, S. Intrathymically expressed c-kit ligand (stem cell
factor) is a major factor driving expansion of very immature thymocytes in vivo. Immunity 1995, 3, 313–319.
[CrossRef]
13. Koch, U.; Fiorini, E.; Benedito, R.; Besseyrias, V.; Schuster-Gossler, K.; Pierres, M.; Manley, N.R.; Duarte, A.;
Macdonald, H.R.; Radtke, F. Delta-like 4 is the essential, nonredundant ligand for NOTCH1 during thymic T
cell lineage commitment. J. Exp. Med. 2008, 205, 2515–2523. [CrossRef] [PubMed]
14. Weerkamp, F.; Pike-Overzet, K.; Staal, F.J. T-sing progenitors to commit. Trends Immunol. 2006, 27, 125–131.
[CrossRef] [PubMed]
15. Shah, D.K.; Zuniga-Pflucker, J.C. An overview of the intrathymic intricacies of T cell development. J. Immunol.
2014, 192, 4017–4023. [CrossRef] [PubMed]
16. Von Boehmer, H. Unique features of the pre-T-cell receptor α-chain: Not just a surrogate. Nat. Rev. Immunol.
2005, 5, 571–577. [CrossRef] [PubMed]
17. Ciofani, M.; Zuniga-Pflucker, J.C. NOTCH promotes survival of pre-T cells at the β-selection checkpoint by
regulating cellular metabolism. Nat. Immunol. 2005, 6, 881–888. [CrossRef] [PubMed]
18. Begley, C.G.; Aplan, P.D.; Davey, M.P.; Nakahara, K.; Tchorz, K.; Kurtzberg, J.; Hershfield, M.S.; Haynes, B.F.;
Cohen, D.I.; Waldmann, T.A.; et al. Chromosomal translocation in a human leukemic stem-cell line disrupts
the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion
transcript. Proc. Natl. Acad. Sci. USA 1989, 86, 2031–2035. [CrossRef] [PubMed]
19. Xia, Y.; Brown, L.; Yang, C.Y.; Tsan, J.T.; Siciliano, M.J.; Espinosa, R., 3rd; Le Beau, M.M.; Baer, R.J.
TAL2, a helix-loop-helix gene activated by the (7;9)(q34;q32) translocation in human T-cell leukemia.
Proc. Natl. Acad. Sci. USA 1991, 88, 11416–11420. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1904 17 of 29
20. Mellentin, J.D.; Smith, S.D.; Cleary, M.L. lyl-1, a novel gene altered by chromosomal translocation in T cell
leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell 1989, 58, 77–83. [CrossRef]
21. Wang, J.; Jani-Sait, S.N.; Escalon, E.A.; Carroll, A.J.; de Jong, P.J.; Kirsch, I.R.; Aplan, P.D.
The t(14;21)(q11.2;q22) chromosomal translocation associated with T-cell acute lymphoblastic leukemia
activates the BHLHB1 gene. Proc. Natl. Acad. Sci. USA 2000, 97, 3497–3502. [CrossRef] [PubMed]
22. Royer-Pokora, B.; Loos, U.; Ludwig, W.D. TTG-2, a new gene encoding a cysteine-rich protein with the LIM
motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 1991, 6, 1887–1893.
[PubMed]
23. McGuire, E.A.; Hockett, R.D.; Pollock, K.M.; Bartholdi, M.F.; O’Brien, S.J.; Korsmeyer, S.J.
The t(11;14)(p15;q11) in a T-cell acute lymphoblastic leukemia cell line activates multiple transcripts,
including Ttg-1, a gene encoding a potential zinc finger protein. Mol. Cell. Biol. 1989, 9, 2124–2132.
[CrossRef] [PubMed]
24. Hatano, M.; Roberts, C.W.; Minden, M.; Crist, W.M.; Korsmeyer, S.J. Deregulation of a homeobox gene,
HOX11, by the t(10;14) in T cell leukemia. Science 1991, 253, 79–82. [CrossRef] [PubMed]
25. Bernard, O.A.; Busson-LeConiat, M.; Ballerini, P.; Mauchauffe, M.; Della Valle, V.; Monni, R.; Nguyen Khac, F.;
Mercher, T.; Penard-Lacronique, V.; Pasturaud, P.; et al. A new recurrent and specific cryptic translocation,
t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia.
Leukemia 2001, 15, 1495–1504. [CrossRef] [PubMed]
26. Homminga, I.; Pieters, R.; Langerak, A.W.; de Rooi, J.J.; Stubbs, A.; Verstegen, M.; Vuerhard, M.;
Buijs-Gladdines, J.; Kooi, C.; Klous, P.; et al. Integrated transcript and genome analyses reveal NKX2-1
and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell 2011, 19, 484–497.
[CrossRef] [PubMed]
27. Nagel, S.; Kaufmann, M.; Drexler, H.G.; MacLeod, R.A. The cardiac homeobox gene NKX2-5 is deregulated
by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2). Cancer Res. 2003,
63, 5329–5334. [PubMed]
28. Soulier, J.; Clappier, E.; Cayuela, J.M.; Regnault, A.; Garcia-Peydro, M.; Dombret, H.; Baruchel, A.;
Toribio, M.L.; Sigaux, F. HOXA genes are included in genetic and biologic networks defining human
acute T-cell leukemia (T-ALL). Blood 2005, 106, 274–286. [CrossRef] [PubMed]
29. Erikson, J.; Finger, L.; Sun, L.; ar-Rushdi, A.; Nishikura, K.; Minowada, J.; Finan, J.; Emanuel, B.S.;
Nowell, P.C.; Croce, C.M. Deregulation of c-myc by translocation of the α-locus of the T-cell receptor
in T-cell leukemias. Science 1986, 232, 884–886. [CrossRef] [PubMed]
30. Clappier, E.; Cuccuini, W.; Kalota, A.; Crinquette, A.; Cayuela, J.M.; Dik, W.A.; Langerak, A.W.;
Montpellier, B.; Nadel, B.; Walrafen, P.; et al. The C-MYB locus is involved in chromosomal translocation
and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL
subtype in very young children. Blood 2007, 110, 1251–1261. [CrossRef] [PubMed]
31. Mullighan, C.G.; Goorha, S.; Radtke, I.; Miller, C.B.; Coustan-Smith, E.; Dalton, J.D.; Girtman, K.; Mathew, S.;
Ma, J.; Pounds, S.B.; et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.
Nature 2007, 446, 758–764. [CrossRef] [PubMed]
32. Graux, C.; Cools, J.; Melotte, C.; Quentmeier, H.; Ferrando, A.; Levine, R.; Vermeesch, J.R.; Stul, M.; Dutta, B.;
Boeckx, N.; et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.
Nat. Genet. 2004, 36, 1084–1089. [CrossRef] [PubMed]
33. Van Limbergen, H.; Beverloo, H.B.; van Drunen, E.; Janssens, A.; Hahlen, K.; Poppe, B.; Van Roy, N.;
Marynen, P.; De Paepe, A.; Slater, R.; et al. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive
leukemia. Genes Chromosomes Cancer 2001, 30, 274–282. [CrossRef]
34. Remke, M.; Pfister, S.; Kox, C.; Toedt, G.; Becker, N.; Benner, A.; Werft, W.; Breit, S.; Liu, S.; Engel, F.; et al.
High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting
the TGF-β and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early
treatment response. Blood 2009, 114, 1053–1062. [CrossRef] [PubMed]
35. Ntziachristos, P.; Tsirigos, A.; Welstead, G.G.; Trimarchi, T.; Bakogianni, S.; Xu, L.; Loizou, E.; Holmfeldt, L.;
Strikoudis, A.; King, B.; et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic
leukaemia. Nature 2014, 514, 513–517. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1904 18 of 29
36. Van Vlierberghe, P.; Palomero, T.; Khiabanian, H.; Van der Meulen, J.; Castillo, M.; Van Roy, N.; De
Moerloose, B.; Philippe, J.; Gonzalez-Garcia, S.; Toribio, M.L.; et al. PHF6 mutations in T-cell acute
lymphoblastic leukemia. Nat. Genet. 2010, 42, 338–342. [CrossRef] [PubMed]
37. Van der Meulen, J.; Sanghvi, V.; Mavrakis, K.; Durinck, K.; Fang, F.; Matthijssens, F.; Rondou, P.; Rosen, M.;
Pieters, T.; Vandenberghe, P.; et al. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor
in T-cell acute lymphoblastic leukemia. Blood 2015, 125, 13–21. [CrossRef] [PubMed]
38. Huether, R.; Dong, L.; Chen, X.; Wu, G.; Parker, M.; Wei, L.; Ma, J.; Edmonson, M.N.; Hedlund, E.K.;
Rusch, M.C.; et al. The landscape of somatic mutations in epigenetic regulators across 1000 paediatric cancer
genomes. Nat. Commun. 2014, 5, 3630. [CrossRef] [PubMed]
39. Thalhammer-Scherrer, R.; Mitterbauer, G.; Simonitsch, I.; Jaeger, U.; Lechner, K.; Schneider, B.; Fonatsch, C.;
Schwarzinger, I. The immunophenotype of 325 adult acute leukemias: Relationship to morphologic and
molecular classification and proposal for a minimal screening program highly predictive for lineage
discrimination. Am. J. Clin. Pathol. 2002, 117, 380–389. [CrossRef] [PubMed]
40. Durinck, K.; Goossens, S.; Peirs, S.; Wallaert, A.; Van Loocke, W.; Matthijssens, F.; Pieters, T.; Milani, G.;
Lammens, T.; Rondou, P.; et al. Novel biological insights in T-cell acute lymphoblastic leukemia. Exp. Hematol.
2015, 43, 625–639. [CrossRef] [PubMed]
41. Liu, Y.; Easton, J.; Shao, Y.; Maciaszek, J.; Wang, Z.; Wilkinson, M.R.; McCastlain, K.; Edmonson, M.;
Pounds, S.B.; Shi, L.; et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic
leukemia. Nat. Genet. 2017, 49, 1211–1218. [CrossRef] [PubMed]
42. Zhang, J.; Ding, L.; Holmfeldt, L.; Wu, G.; Heatley, S.L.; Payne-Turner, D.; Easton, J.; Chen, X.; Wang, J.;
Rusch, M.; et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481,
157–163. [CrossRef] [PubMed]
43. De Keersmaecker, K.; Atak, Z.K.; Li, N.; Vicente, C.; Patchett, S.; Girardi, T.; Gianfelici, V.; Geerdens, E.;
Clappier, E.; Porcu, M.; et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5
and RPL10 in T-cell acute lymphoblastic leukemia. Nat. Genet. 2013, 45, 186–190. [CrossRef] [PubMed]
44. Holmfeldt, L.; Wei, L.; Diaz-Flores, E.; Walsh, M.; Zhang, J.; Ding, L.; Payne-Turner, D.; Churchman, M.;
Andersson, A.; Chen, S.C.; et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia.
Nat. Genet. 2013, 45, 242–252. [CrossRef] [PubMed]
45. Girardi, T.; Vicente, C.; Cools, J.; De Keersmaecker, K. The genetics and molecular biology of T-ALL. Blood
2017, 129, 1113–1123. [CrossRef] [PubMed]
46. Tosello, V.; Mansour, M.R.; Barnes, K.; Paganin, M.; Sulis, M.L.; Jenkinson, S.; Allen, C.G.; Gale, R.E.;
Linch, D.C.; Palomero, T.; et al. WT1 mutations in T-ALL. Blood 2009, 114, 1038–1045. [CrossRef] [PubMed]
47. Oliveira, M.L.; Akkapeddi, P.; Alcobia, I.; Almeida, A.R.; Cardoso, B.A.; Fragoso, R.; Serafim, T.L.; Barata, J.T.
From the outside, from within: Biological and therapeutic relevance of signal transduction in T-cell acute
lymphoblastic leukemia. Cell Signal. 2017, 38, 10–25. [CrossRef] [PubMed]
48. Van der Meulen, J.; van Roy, N.; van Vlierberghe, P.; Speleman, F. The epigenetic landscape of T-cell acute
lymphoblastic leukemia. Int. J. Biochem. Cell Biol. 2014, 53, 547–557. [CrossRef] [PubMed]
49. Radtke, F.; Wilson, A.; Stark, G.; Bauer, M.; van Meerwijk, J.; MacDonald, H.R.; Aguet, M. Deficient T cell
fate specification in mice with an induced inactivation of NOTCH1. Immunity 1999, 10, 547–558. [CrossRef]
50. Ellisen, L.W.; Bird, J.; West, D.C.; Soreng, A.L.; Reynolds, T.C.; Smith, S.D.; Sklar, J. TAN-1, the human
homolog of the Drosophila NOTCH gene, is broken by chromosomal translocations in T lymphoblastic
neoplasms. Cell 1991, 66, 649–661. [CrossRef]
51. O’Neil, J.; Grim, J.; Strack, P.; Rao, S.; Tibbitts, D.; Winter, C.; Hardwick, J.; Welcker, M.; Meijerink, J.P.;
Pieters, R.; et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to
γ-secretase inhibitors. J. Exp. Med. 2007, 204, 1813–1824. [CrossRef] [PubMed]
52. Thompson, B.J.; Buonamici, S.; Sulis, M.L.; Palomero, T.; Vilimas, T.; Basso, G.; Ferrando, A.; Aifantis, I.
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 2007,
204, 1825–1835. [CrossRef] [PubMed]
53. Bernasconi-Elias, P.; Hu, T.; Jenkins, D.; Firestone, B.; Gans, S.; Kurth, E.; Capodieci, P.; Deplazes-Lauber, J.;
Petropoulos, K.; Thiel, P.; et al. Characterization of activating mutations of NOTCH3 in T-cell acute
lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene 2016,
35, 6077–6086. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1904 19 of 29
54. Xiong, H.; Maraver, A.; Latkowski, J.A.; Henderson, T.; Schlessinger, K.; Ding, Y.; Shen, J.; Tadokoro, C.E.;
Lafaille, J.J. Characterization of two distinct lymphoproliferative diseases caused by ectopic expression of the
NOTCH ligand DLL4 on T cells. PLoS ONE 2013, 8, e84841. [CrossRef] [PubMed]
55. Sanchez-Martin, M.; Ferrando, A. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia.
Blood 2017, 129, 1124–1133. [CrossRef] [PubMed]
56. Palomero, T.; Lim, W.K.; Odom, D.T.; Sulis, M.L.; Real, P.J.; Margolin, A.; Barnes, K.C.; O’Neil, J.; Neuberg, D.;
Weng, A.P.; et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional
network promoting leukemic cell growth. Proc. Natl. Acad. Sci. USA 2006, 103, 18261–18266. [CrossRef]
[PubMed]
57. Weng, A.P.; Millholland, J.M.; Yashiro-Ohtani, Y.; Arcangeli, M.L.; Lau, A.; Wai, C.; Del Bianco, C.;
Rodriguez, C.G.; Sai, H.; Tobias, J.; et al. c-Myc is an important direct target of NOTCH1 in T-cell acute
lymphoblastic leukemia/lymphoma. Genes Dev. 2006, 20, 2096–2109. [CrossRef] [PubMed]
58. Herranz, D.; Ambesi-Impiombato, A.; Palomero, T.; Schnell, S.A.; Belver, L.; Wendorff, A.A.; Xu, L.;
Castillo-Martin, M.; Llobet-Navas, D.; Cordon-Cardo, C.; et al. A NOTCH1-driven MYC enhancer promotes
T cell development, transformation and acute lymphoblastic leukemia. Nat. Med. 2014, 20, 1130–1137.
[CrossRef] [PubMed]
59. Yashiro-Ohtani, Y.; Wang, H.; Zang, C.; Arnett, K.L.; Bailis, W.; Ho, Y.; Knoechel, B.; Lanauze, C.; Louis, L.;
Forsyth, K.S.; et al. Long-range enhancer activity determines Myc sensitivity to NOTCH inhibitors in T cell
leukemia. Proc. Natl. Acad. Sci. USA 2014, 111, E4946–E4953. [CrossRef] [PubMed]
60. Real, P.J.; Tosello, V.; Palomero, T.; Castillo, M.; Hernando, E.; de Stanchina, E.; Sulis, M.L.; Barnes, K.;
Sawai, C.; Homminga, I.; et al. γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute
lymphoblastic leukemia. Nat. Med. 2009, 15, 50–58. [CrossRef] [PubMed]
61. Yoon, S.O.; Zapata, M.C.; Singh, A.; Jo, W.S.; Spencer, N.; Choi, Y.S. γ secretase
inhibitors enhance vincristine-induced apoptosis in T-ALL in a NOTCH-independent
manner. Apoptosis Int. J. Program. Cell Death 2014, 19, 1616–1626. [CrossRef] [PubMed]
62. Samon, J.B.; Castillo-Martin, M.; Hadler, M.; Ambesi-Impiobato, A.; Paietta, E.; Racevskis, J.; Wiernik, P.H.;
Rowe, J.M.; Jakubczak, J.; Randolph, S.; et al. Preclinical analysis of the γ-secretase inhibitor PF-03084014
in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol. Cancer Ther. 2012,
11, 1565–1575. [CrossRef] [PubMed]
63. Wu, Y.; Cain-Hom, C.; Choy, L.; Hagenbeek, T.J.; de Leon, G.P.; Chen, Y.; Finkle, D.; Venook, R.;
Wu, X.; Ridgway, J.; et al. Therapeutic antibody targeting of individual NOTCH receptors. Nature 2010,
464, 1052–1057. [CrossRef] [PubMed]
64. Agnusdei, V.; Minuzzo, S.; Frasson, C.; Grassi, A.; Axelrod, F.; Satyal, S.; Gurney, A.; Hoey, T.; Seganfreddo, E.;
Basso, G.; et al. Therapeutic antibody targeting of NOTCH 1 in T-acute lymphoblastic leukemia xenografts.
Leukemia 2014, 28, 278–288. [CrossRef] [PubMed]
65. Moellering, R.E.; Cornejo, M.; Davis, T.N.; Del Bianco, C.; Aster, J.C.; Blacklow, S.C.; Kung, A.L.;
Gilliland, D.G.; Verdine, G.L.; Bradner, J.E. Direct inhibition of the NOTCH transcription factor complex.
Nature 2009, 462, 182–188. [CrossRef] [PubMed]
66. Medyouf, H.; Gusscott, S.; Wang, H.; Tseng, J.C.; Wai, C.; Nemirovsky, O.; Trumpp, A.; Pflumio, F.; Carboni, J.;
Gottardis, M.; et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL
and is supported by NOTCH signaling. J. Exp. Med. 2011, 208, 1809–1822. [CrossRef] [PubMed]
67. Roti, G.; Carlton, A.; Ross, K.N.; Markstein, M.; Pajcini, K.; Su, A.H.; Perrimon, N.; Pear, W.S.; Kung, A.L.;
Blacklow, S.C.; et al. Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1
mutated cancer. Cancer Cell 2013, 23, 390–405. [CrossRef] [PubMed]
68. Wendorff, A.A.; Koch, U.; Wunderlich, F.T.; Wirth, S.; Dubey, C.; Bruning, J.C.; MacDonald, H.R.; Radtke, F.
Hes1 is a critical but context-dependent mediator of canonical NOTCH signaling in lymphocyte development
and transformation. Immunity 2010, 33, 671–684. [CrossRef] [PubMed]
69. Schnell, S.A.; Ambesi-Impiombato, A.; Sanchez-Martin, M.; Belver, L.; Xu, L.; Qin, Y.; Kageyama, R.;
Ferrando, A.A. Therapeutic targeting of HES1 transcriptional programs in T-ALL. Blood 2015, 125, 2806–2814.
[CrossRef] [PubMed]
70. Dang, C.V. MYC on the path to cancer. Cell 2012, 149, 22–35. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1904 20 of 29
71. Dose, M.; Khan, I.; Guo, Z.; Kovalovsky, D.; Krueger, A.; von Boehmer, H.; Khazaie, K.; Gounari, F. c-Myc
mediates pre-TCR-induced proliferation but not developmental progression. Blood 2006, 108, 2669–2677.
[CrossRef] [PubMed]
72. Sharma, V.M.; Calvo, J.A.; Draheim, K.M.; Cunningham, L.A.; Hermance, N.; Beverly, L.; Krishnamoorthy, V.;
Bhasin, M.; Capobianco, A.J.; Kelliher, M.A. NOTCH1 contributes to mouse T-cell leukemia by directly
inducing the expression of c-myc. Mol. Cell. Biol. 2006, 26, 8022–8031. [CrossRef] [PubMed]
73. King, B.; Trimarchi, T.; Reavie, L.; Xu, L.; Mullenders, J.; Ntziachristos, P.; Aranda-Orgilles, B.;
Perez-Garcia, A.; Shi, J.; Vakoc, C.; et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell
activity by regulating MYC stability. Cell 2013, 153, 1552–1566. [CrossRef] [PubMed]
74. Loven, J.; Hoke, H.A.; Lin, C.Y.; Lau, A.; Orlando, D.A.; Vakoc, C.R.; Bradner, J.E.; Lee, T.I.; Young, R.A.
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153, 320–334. [CrossRef]
[PubMed]
75. Delmore, J.E.; Issa, G.C.; Lemieux, M.E.; Rahl, P.B.; Shi, J.; Jacobs, H.M.; Kastritis, E.; Gilpatrick, T.;
Paranal, R.M.; Qi, J.; et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011,
146, 904–917. [CrossRef] [PubMed]
76. Okkenhaug, K.; Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation and activation.
Nat. Rev. Immunol. 2003, 3, 317–330. [CrossRef] [PubMed]
77. Thorpe, L.M.; Yuzugullu, H.; Zhao, J.J. PI3K in cancer: Divergent roles of isoforms, modes of activation and
therapeutic targeting. Nat. Rev. Cancer 2015, 15, 7–24. [CrossRef] [PubMed]
78. Manning, B.D.; Toker, A. AKT/PKB signaling: Navigating the network. Cell 2017, 169, 381–405. [CrossRef]
[PubMed]
79. Liu, J.; Farmer, J.D.; Lane, W.S.; Friedman, J.; Weissman, I.; Schreiber, S.L. Calcineurin is a common target
of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66, 807–815. [CrossRef]
80. Juntilla, M.M.; Koretzky, G.A. Critical roles of the PI3K/Akt signaling pathway in T cell development.
Immunol. Lett. 2008, 116, 104–110. [CrossRef] [PubMed]
81. Juntilla, M.M.; Wofford, J.A.; Birnbaum, M.J.; Rathmell, J.C.; Koretzky, G.A. Akt1 and Akt2 are required
for αβ thymocyte survival and differentiation. Proc. Natl. Acad. Sci. USA 2007, 104, 12105–12110. [CrossRef]
[PubMed]
82. Swat, W.; Montgrain, V.; Doggett, T.A.; Douangpanya, J.; Puri, K.; Vermi, W.; Diacovo, T.G. Essential role
of PI3Kdelta and PI3Kγ in thymocyte survival. Blood 2006, 107, 2415–2422. [CrossRef] [PubMed]
83. Buckler, J.L.; Walsh, P.T.; Porrett, P.M.; Choi, Y.; Turka, L.A. Cutting edge: T cell requirement for CD28
costimulation is due to negative regulation of TCR signals by PTEN. J. Immunol. 2006, 177, 4262–4266.
[CrossRef] [PubMed]
84. Kane, L.P.; Andres, P.G.; Howland, K.C.; Abbas, A.K.; Weiss, A. Akt provides the CD28 costimulatory
signal for up-regulation of IL-2 and IFN-γ but not TH2 cytokines. Nat. Immunol. 2001, 2, 37–44. [CrossRef]
[PubMed]
85. Palomero, T.; Sulis, M.L.; Cortina, M.; Real, P.J.; Barnes, K.; Ciofani, M.; Caparros, E.; Buteau, J.; Brown, K.;
Perkins, S.L.; et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.
Nat. Med. 2007, 13, 1203–1210. [CrossRef] [PubMed]
86. Gutierrez, A.; Sanda, T.; Grebliunaite, R.; Carracedo, A.; Salmena, L.; Ahn, Y.; Dahlberg, S.; Neuberg, D.;
Moreau, L.A.; Winter, S.S.; et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute
lymphoblastic leukemia. Blood 2009, 114, 647–650. [CrossRef] [PubMed]
87. Silva, A.; Yunes, J.A.; Cardoso, B.A.; Martins, L.R.; Jotta, P.Y.; Abecasis, M.; Nowill, A.E.; Leslie, N.R.;
Cardoso, A.A.; Barata, J.T. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway
sustain primary T cell leukemia viability. J. Clin. Investig. 2008, 118, 3762–3774. [CrossRef] [PubMed]
88. Maser, R.S.; Choudhury, B.; Campbell, P.J.; Feng, B.; Wong, K.-K.; Protopopov, A.; O’Neil, J.; Gutierrez, A.;
Ivanova, E.; Perna, I.; et al. Chromosomally unstable mouse tumours have genomic alterations similar to
diverse human cancers. Nature 2007, 447, 966–971. [CrossRef] [PubMed]
89. Jotta, P.Y.; Ganazza, M.A.; Silva, A.; Viana, M.B.; da Silva, M.J.; Zambaldi, L.J.G.; Barata, J.T.; Brandalise, S.R.;
Yunes, J.A. Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia.
Leukemia 2009, 24, 239–242. [CrossRef] [PubMed]
90. Mullighan, C.G. The genomic landscape of acute lymphoblastic leukemia in children and young adults.
ASH Educ. Program Book 2014, 2014, 174–180. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1904 21 of 29
91. Barata, J.T.; Silva, A.; Brandao, J.G.; Nadler, L.M.; Cardoso, A.A.; Boussiotis, V.A. Activation of PI3K is
indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute
lymphoblastic leukemia cells. J. Exp. Med. 2004, 200, 659–669. [CrossRef] [PubMed]
92. Johnson, S.E.; Shah, N.; Bajer, A.A.; LeBien, T.W. IL-7 activates the phosphatidylinositol 3-kinase/AKT
pathway in normal human thymocytes but not normal human B cell precursors. J. Immunol. 2008,
180, 8109–8117. [CrossRef] [PubMed]
93. Gonzalez-Garcia, S.; Garcia-Peydro, M.; Martin-Gayo, E.; Ballestar, E.; Esteller, M.; Bornstein, R.;
de la Pompa, J.L.; Ferrando, A.A.; Toribio, M.L. CSL-MAML-dependent NOTCH1 signaling controls T
lineage-specific IL-7R{α} gene expression in early human thymopoiesis and leukemia. J. Exp. Med. 2009, 206,
779–791. [CrossRef] [PubMed]
94. Mavrakis, K.J.; Wolfe, A.L.; Oricchio, E.; Palomero, T.; de Keersmaecker, K.; McJunkin, K.; Zuber, J.; James, T.;
Khan, A.A.; Leslie, C.S.; et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets
in NOTCH-induced T-cell acute lymphoblastic leukaemia. Nat. Cell Biol. 2010, 12, 372–379. [CrossRef]
[PubMed]
95. Gutierrez, A.; Grebliunaite, R.; Feng, H.; Kozakewich, E.; Zhu, S.; Guo, F.; Payne, E.; Mansour, M.;
Dahlberg, S.E.; Neuberg, D.S.; et al. Pten mediates Myc oncogene dependence in a conditional zebrafish
model of T cell acute lymphoblastic leukemia. J. Exp. Med. 2011, 208, 1595–1603. [CrossRef] [PubMed]
96. Hales, E.C.; Orr, S.M.; Larson Gedman, A.; Taub, J.W.; Matherly, L.H. NOTCH1 receptor regulates AKT
protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in
phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells. J. Biol. Chem.
2013, 288, 22836–22848. [CrossRef] [PubMed]
97. Grimberg, A. Mechanisms by which IGF-I may promote cancer. Cancer Biol. Ther. 2003, 2, 630–635. [CrossRef]
[PubMed]
98. Gusscott, S.; Kuchenbauer, F.; Humphries, R.K.; Weng, A.P. NOTCH-mediated repression of miR-223
contributes to IGF1R regulation in T-ALL. Leukemia Res. 2012, 36, 905–911. [CrossRef] [PubMed]
99. Trimarchi, T.; Bilal, E.; Ntziachristos, P.; Fabbri, G.; Dalla-Favera, R.; Tsirigos, A.; Aifantis, I. Genome-wide
mapping and characterization of NOTCH-regulated long noncoding RNAs in acute leukemia. Cell 2014,
158, 593–606. [CrossRef] [PubMed]
100. Hoshii, T.; Kasada, A.; Hatakeyama, T.; Ohtani, M.; Tadokoro, Y.; Naka, K.; Ikenoue, T.; Ikawa, T.;
Kawamoto, H.; Fehling, H.J.; et al. Loss of mTOR complex 1 induces developmental blockage in early
T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells. Proc. Natl. Acad. Sci. USA 2014,
111, 3805–3810. [CrossRef] [PubMed]
101. Wei, G.; Twomey, D.; Lamb, J.; Schlis, K.; Agarwal, J.; Stam, R.W.; Opferman, J.T.; Sallan, S.E.; den Boer, M.L.;
Pieters, R.; et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1
and glucocorticoid resistance. Cancer Cell 2006, 10, 331–342. [CrossRef] [PubMed]
102. Easton, J.B.; Houghton, P.J. mTOR and cancer therapy. Oncogene 2006, 25, 6436–6446. [CrossRef] [PubMed]
103. Lonetti, A.; Antunes, I.L.; Chiarini, F.; Orsini, E.; Buontempo, F.; Ricci, F.; Tazzari, P.L.; Pagliaro, P.;
Melchionda, F.; Pession, A.; et al. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120
in T-cell acute lymphoblastic leukemia. Leukemia 2014, 28, 1196–1206. [CrossRef] [PubMed]
104. Lonetti, A.; Cappellini, A.; Sparta, A.M.; Chiarini, F.; Buontempo, F.; Evangelisti, C.; Orsini, E.; McCubrey, J.A.;
Martelli, A.M. PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute
lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. Oncotarget 2015,
6, 10399–10414. [CrossRef] [PubMed]
105. Subramaniam, P.S.; Whye, D.W.; Efimenko, E.; Chen, J.; Tosello, V.; De Keersmaecker, K.; Kashishian, A.;
Thompson, M.A.; Castillo, M.; Cordon-Cardo, C.; et al. Targeting nonclassical oncogenes for therapy
in T-ALL. Cancer Cell 2012, 21, 459–472. [CrossRef] [PubMed]
106. Simioni, C.; Neri, L.M.; Tabellini, G.; Ricci, F.; Bressanin, D.; Chiarini, F.; Evangelisti, C.; Cani, A.; Tazzari, P.L.;
Melchionda, F.; et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic
leukemia. Leukemia 2012, 26, 2336–2342. [CrossRef] [PubMed]
107. Piovan, E.; Yu, J.; Tosello, V.; Herranz, D.; Ambesi-Impiombato, A.; Da Silva, A.C.; Sanchez-Martin, M.;
Perez-Garcia, A.; Rigo, I.; Castillo, M.; et al. Direct reversal of glucocorticoid resistance by AKT inhibition
in acute lymphoblastic leukemia. Cancer Cell 2013, 24, 766–776. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1904 22 of 29
108. Shepherd, C.; Banerjee, L.; Cheung, C.W.; Mansour, M.R.; Jenkinson, S.; Gale, R.E.; Khwaja, A. PI3K/mTOR
inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Leukemia 2013,
27, 650–660. [CrossRef] [PubMed]
109. Chiarini, F.; Fala, F.; Tazzari, P.L.; Ricci, F.; Astolfi, A.; Pession, A.; Pagliaro, P.; McCubrey, J.A.; Martelli, A.M.
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new
therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res. 2009, 69, 3520–3528. [CrossRef]
[PubMed]
110. Fransecky, L.; Mochmann, L.H.; Baldus, C.D. Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.
Mol. Cell. Ther. 2015, 3, 2. [CrossRef] [PubMed]
111. Jiang, Q.; Li, W.Q.; Aiello, F.B.; Mazzucchelli, R.; Asefa, B.; Khaled, A.R.; Durum, S.K. Cell biology of IL-7,
a key lymphotrophin. Cytokine Growth Factor Rev. 2005, 16, 513–533. [CrossRef] [PubMed]
112. ElKassar, N.; Gress, R.E. An overview of IL-7 biology and its use in immunotherapy. J. Immunotoxicol. 2010,
7, 1–7. [CrossRef] [PubMed]
113. Mazzucchelli, R.; Durum, S.K. Interleukin-7 receptor expression: Intelligent design. Nat. Rev. Immunol. 2007,
7, 144–154. [CrossRef] [PubMed]
114. Von Freeden-Jeffry, U.; Vieira, P.; Lucian, L.A.; McNeil, T.; Burdach, S.E.; Murray, R. Lymphopenia
in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J. Exp. Med. 1995,
181, 1519–1526. [CrossRef] [PubMed]
115. Peschon, J.J. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.
J. Exp. Med. 1994, 180, 1955–1960. [CrossRef] [PubMed]
116. Puel, A.; Ziegler, S.F.; Buckley, R.H.; Leonard, W.J. Defective IL7R expression in T(−)B(+)NK(+) severe
combined immunodeficiency. Nat. Genet. 1998, 20, 394–397. [PubMed]
117. Noguchi, M.; Yi, H.; Rosenblatt, H.M.; Filipovich, A.H.; Adelstein, S.; Modi, W.S.; McBride, O.W.;
Leonard, W.J. Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency
in humans. Cell 1993, 73, 147–157. [CrossRef]
118. Rich, B.E.; Campos-Torres, J.; Tepper, R.I.; Moreadith, R.W.; Leder, P. Cutaneous lymphoproliferation and
lymphomas in interleukin 7 transgenic mice. J. Exp. Med. 1993, 177, 305–316. [CrossRef] [PubMed]
119. Abraham, N.; Ma, M.C.; Snow, J.W.; Miners, M.J.; Herndier, B.G.; Goldsmith, M.A. Haploinsufficiency
identifies STAT5 as a modifier of IL-7-induced lymphomas. Oncogene 2005, 24, 5252–5257. [CrossRef]
[PubMed]
120. Dibirdik, I.; Langlie, M.C.; Ledbetter, J.A.; Tuel-Ahlgren, L.; Obuz, V.; Waddick, K.G.; Gajl-Peczalska, K.;
Schieven, G.L.; Uckun, F.M. Engagement of interleukin-7 receptor stimulates tyrosine phosphorylation,
phosphoinositide turnover, and clonal proliferation of human T-lineage acute lymphoblastic leukemia cells.
Blood 1991, 78, 564–570. [PubMed]
121. Touw, I.; Pouwels, K.; van Agthoven, T.; van Gurp, R.; Budel, L.; Hoogerbrugge, H.; Delwel, R.; Goodwin, R.;
Namen, A.; Löwenberg, B. Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia.
Blood 1990, 75, 2097–2101. [PubMed]
122. Digel, W.; Schmid, M.; Heil, G.; Conrad, P.; Gillis, S.; Porzsolt, F. Human interleukin-7 induces proliferation
of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood 1991, 78, 753–759.
[PubMed]
123. Silva, A.; Laranjeira, A.B.A.; Martins, L.R.; Cardoso, B.A.; Demengeot, J.; Andrés Yunes, J.; Seddon, B.;
Barata, J.T. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res.
2011, 71, 4780–4789. [CrossRef] [PubMed]
124. Barata, J.T.; Cardoso, A.A.; Nadler, L.M.; Boussiotis, V.A. Interleukin-7 promotes survival and cell cycle
progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase
inhibitor p27(kip1). Blood 2001, 98, 1524–1531. [CrossRef] [PubMed]
125. Silva, A.; Gírio, A.; Cebola, I.; Santos, C.I.; Antunes, F.; Barata, J.T. Intracellular reactive oxygen species are
essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia
cells. Leukemia 2011, 25, 960–967. [CrossRef] [PubMed]
126. Zenatti, P.P.; Ribeiro, D.; Li, W.; Zuurbier, L.; Silva, M.C.; Paganin, M.; Tritapoe, J.; Hixon, J.A.; Silveira, A.B.;
Cardoso, B.A.; et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic
leukemia. Nat. Genet. 2011, 43, 932–939. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1904 23 of 29
127. Shochat, C.; Tal, N.; Bandapalli, O.R.; Palmi, C.; Ganmore, I.; te Kronnie, G.; Cario, G.; Cazzaniga, G.;
Kulozik, A.E.; Stanulla, M.; et al. Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood
acute lymphoblastic leukemias. J. Exp. Med. 2011, 208, 901–908. [CrossRef] [PubMed]
128. Flex, E.; Petrangeli, V.; Stella, L.; Chiaretti, S.; Hornakova, T.; Knoops, L.; Ariola, C.; Fodale, V.; Clappier, E.;
Paoloni, F.; et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J. Exp. Med.
2008, 205, 751–758. [CrossRef] [PubMed]
129. Bains, T.; Heinrich, M.C.; Loriaux, M.M.; Beadling, C.; Nelson, D.; Warrick, A.; Neff, T.L.; Tyner, J.W.;
Dunlap, J.; Corless, C.L.; et al. Newly described activating JAK3 mutations in T-cell acute lymphoblastic
leukemia. Leukemia 2012, 26, 2144–2146. [CrossRef] [PubMed]
130. Kontro, M.; Kuusanmaki, H.; Eldfors, S.; Pemovska, T.; Rajala, H.L.M.; Edgren, H.; Ellonen, P.; Lagstrom, S.;
Lundan, T.; Kallioniemi, O.; et al. Novel Activating STAT5B Mutations As Drivers Of T-ALL. Blood 2013,
122, 3863.
131. Bandapalli, O.R.; Schuessele, S.; Kunz, J.B.; Rausch, T.; Stutz, A.M.; Tal, N.; Geron, I.; Gershman, N.; Izraeli, S.;
Eilers, J.; et al. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute
lymphoblastic leukemia and confers a higher risk of relapse. Haematologica 2014, 99, e188–e192. [CrossRef]
[PubMed]
132. Lacronique, V.; Boureux, A.; Valle, V.D.; Poirel, H.; Quang, C.T.; Mauchauffe, M.; Berthou, C.; Lessard, M.;
Berger, R.; Ghysdael, J.; et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.
Science 1997, 278, 1309–1312. [CrossRef] [PubMed]
133. Onnebo, S.M.; Rasighaemi, P.; Kumar, J.; Liongue, C.; Ward, A.C. Alternative TEL-JAK2 fusions associated
with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish.
Haematologica 2012, 97, 1895–1903. [CrossRef] [PubMed]
134. Kleppe, M.; Lahortiga, I.; El Chaar, T.; De Keersmaecker, K.; Mentens, N.; Graux, C.; Van Roosbroeck, K.;
Ferrando, A.A.; Langerak, A.W.; Meijerink, J.P.; et al. Deletion of the protein tyrosine phosphatase gene
PTPN2 in T-cell acute lymphoblastic leukemia. Nat. Genet. 2010, 42, 530–535. [CrossRef] [PubMed]
135. Kleppe, M.; Soulier, J.; Asnafi, V.; Mentens, N.; Hornakova, T.; Knoops, L.; Constantinescu, S.; Sigaux, F.;
Meijerink, J.P.; Vandenberghe, P.; et al. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute
lymphoblastic leukemia. Blood 2011, 117, 7090–7098. [CrossRef] [PubMed]
136. Tremblay, C.S.; Brown, F.C.; Collett, M.; Saw, J.; Chiu, S.K.; Sonderegger, S.E.; Lucas, S.E.; Alserihi, R.;
Chau, N.; Toribio, M.L.; et al. Loss-of-function mutations of Dynamin 2 promote T-ALL by enhancing IL-7
signalling. Leukemia 2016, 30, 1993–2001. [CrossRef] [PubMed]
137. Goossens, S.; Radaelli, E.; Blanchet, O.; Durinck, K.; Van der Meulen, J.; Peirs, S.; Taghon, T.; Tremblay, C.S.;
Costa, M.; Farhang Ghahremani, M.; et al. ZEB2 drives immature T-cell lymphoblastic leukaemia
development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nat. Commun. 2015,
6, 5794. [CrossRef] [PubMed]
138. Meyer, S.C.; Levine, R.L. Molecular pathways: Molecular basis for sensitivity and resistance to JAK kinase
inhibitors. Clin. Cancer Res. 2014, 20, 2051–2059. [CrossRef] [PubMed]
139. Passamonti, F.; Vannucchi, A.M.; Cervantes, F.; Harrison, C.; Morra, E.; Kantarjian, H.; Verstovsek, S.
Ruxolitinib and survival improvement in patients with myelofibrosis. Leukemia 2015, 29, 739–740. [CrossRef]
[PubMed]
140. Maude, S.L.; Dolai, S.; Delgado-Martin, C.; Vincent, T.; Robbins, A.; Selvanathan, A.; Ryan, T.; Hall, J.;
Wood, A.C.; Tasian, S.K.; et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of
early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood 2015, 125, 1759–1767. [CrossRef] [PubMed]
141. Li, Y.; Buijs-Gladdines, J.G.; Cante-Barrett, K.; Stubbs, A.P.; Vroegindeweij, E.M.; Smits, W.K.; van Marion, R.;
Dinjens, W.N.; Horstmann, M.; Kuiper, R.P.; et al. IL-7 Receptor Mutations and Steroid Resistance in
Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study. PLoS Med. 2016, 13, e1002200.
[CrossRef] [PubMed]
142. Ward, A.F.; Braun, B.S.; Shannon, K.M. Targeting oncogenic Ras signaling in hematologic malignancies. Blood
2012, 120, 3397–3406. [CrossRef] [PubMed]
143. Irving, J.; Matheson, E.; Minto, L.; Blair, H.; Case, M.; Halsey, C.; Swidenbank, I.; Ponthan, F.;
Kirschner-Schwabe, R.; Groeneveld-Krentz, S.; et al. Ras pathway mutations are prevalent in relapsed
childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 2014, 124, 3420–3430.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1904 24 of 29
144. Oshima, K.; Khiabanian, H.; da Silva-Almeida, A.C.; Tzoneva, G.; Abate, F.; Ambesi-Impiombato, A.;
Sanchez-Martin, M.; Carpenter, Z.; Penson, A.; Perez-Garcia, A.; et al. Mutational landscape, clonal evolution
patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA
2016, 113, 11306–11311. [CrossRef] [PubMed]
145. Kindler, T.; Cornejo, M.G.; Scholl, C.; Liu, J.; Leeman, D.S.; Haydu, J.E.; Fröhling, S.; Lee, B.H.; Gilliland, D.G.
K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor NOTCH1 mutations and are
sensitive to {γ}-secretase inhibitors. Blood 2008, 112, 3373–3382. [CrossRef] [PubMed]
146. Kong, G.; Du, J.; Liu, Y.; Meline, B.; Chang, Y.I.; Ranheim, E.A.; Wang, J.; Zhang, J. NOTCH1 gene mutations
target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation. J. Biol. Chem.
2013, 288, 18219–18227. [CrossRef] [PubMed]
147. Von Lintig, F.C.; Huvar, I.; Law, P.; Diccianni, M.B.; Yu, A.L.; Boss, G.R. Ras activation in normal white blood
cells and childhood acute lymphoblastic leukemia. Clin. Cancer Res. 2000, 6, 1804–1810. [PubMed]
148. Yokota, S.; Nakao, M.; Horiike, S.; Seriu, T.; Iwai, T.; Kaneko, H.; Azuma, H.; Oka, T.; Takeda, T.;
Watanabe, A.; et al. Mutational analysis of the N-ras gene in acute lymphoblastic leukemia: A study of
125 Japanese pediatric cases. Int. J. Hematol. 1998, 67, 379–387. [CrossRef]
149. Perentesis, J.P.; Bhatia, S.; Boyle, E.; Shao, Y.; Shu, X.O.; Steinbuch, M.; Sather, H.N.; Gaynon, P.; Kiffmeyer, W.;
Envall-Fox, J.; et al. RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic
leukemia. Leukemia 2004, 18, 685–692. [CrossRef] [PubMed]
150. Wiemels, J.L.; Zhang, Y.; Chang, J.; Zheng, S.; Metayer, C.; Zhang, L.; Smith, M.T.; Ma, X.; Selvin, S.;
Buffler, P.A.; et al. RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric
acute lymphoblastic leukemia. Leukemia 2005, 19, 415–419. [CrossRef] [PubMed]
151. Balgobind, B.V.; Van Vlierberghe, P.; Van Den Ouweland, A.M.W.; Beverloo, H.B.;
Terlouw-Kromosoeto, J.N.R.; Van Wering, E.R.; Reinhardt, D.; Horstmann, M.; Kaspers, G.J.L.;
Pieters, R.; et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking
evidence for neurofibromatosis. Blood 2008, 111, 4322–4328. [CrossRef] [PubMed]
152. Lubeck, B.A.; Lapinski, P.E.; Oliver, J.A.; Ksionda, O.; Parada, L.F.; Zhu, Y.; Maillard, I.; Chiang, M.; Roose, J.;
King, P.D. Cutting Edge: Codeletion of the Ras GTPase-Activating Proteins (RasGAPs) Neurofibromin 1 and
p120 RasGAP in T Cells Results in the Development of T Cell Acute Lymphoblastic Leukemia. J. Immunol.
2015, 195, 31–35. [CrossRef] [PubMed]
153. Dower, N.A.; Stang, S.L.; Bottorff, D.A.; Ebinu, J.O.; Dickie, P.; Ostergaard, H.L.; Stone, J.C. RasGRP is
essential for mouse thymocyte differentiation and TCR signaling. Nat. Immunol. 2000, 1, 317–321. [CrossRef]
[PubMed]
154. Mues, M.; Roose, J.P. Distinct oncogenic Ras signals characterized by profound differences in flux through
the RasGDP/RasGTP cycle. Small GTPases 2017, 8, 20–25. [CrossRef] [PubMed]
155. Ksionda, O.; Melton, A.; Bache, J.; Tenhagen, M.; Bakker, J.; Harvey, R.; Winter, S.; Rubio, I.; Roose, J. RasGRP1
overexpression in T-ALL increases basal nucleotide exchange on Ras rendering the Ras/PI3K/Akt pathway
responsive to protumorigenic cytokines HHS Public Access. Oncogene 2016, 14, 3658–3668. [CrossRef]
[PubMed]
156. Xu, D.; Liu, X.; Yu, W.M.; Meyerson, H.J.; Guo, C.; Gerson, S.L.; Qu, C.K. Non-lineage/stage-restricted
effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of
hematopoietic cells. J. Exp. Med. 2011, 208, 1977–1988. [CrossRef] [PubMed]
157. Hagemeijer, A.; Graux, C. ABL1 rearrangements in T-cell acute lymphoblastic leukemia. Genes Chromosomes
Cancer 2010, 49, 299–308. [PubMed]
158. Mullighan, C.G. The molecular genetic makeup of acute lymphoblastic leukemia. ASH Educ. Program Book
2012, 2012, 389–396.
159. Raanani, P.; Trakhtenbrot, L.; Rechavi, G.; Rosenthal, E.; Avigdor, A.; Brok-Simoni, F.; Leiba, M.; Amariglio, N.;
Nagler, A.; Ben-Bassat, I. Philadelphia-chromosome-positive T-lymphoblastic leukemia: Acute leukemia or
chronic myelogenous leukemia blastic crisis. Acta Haematol. 2005, 113, 181–189. [CrossRef] [PubMed]
160. Graux, C.; Stevens-Kroef, M.; Lafage, M.; Dastugue, N.; Harrison, C.J.; Mugneret, F.; Bahloula, K.; Struski, S.;
Grégoire, M.J.; Nadal, N.; et al. Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene
in T-cell acute lymphoblastic leukemia. Leukemia 2009, 23, 125–133. [CrossRef] [PubMed]
161. Burmeister, T.; Gökbuget, N.; Reinhardt, R.; Rieder, H.; Hoelzer, D.; Schwartz, S. NUP214-ABL1 in adult
T-ALL: The GMALL study group experience. Blood 2006, 108, 3556–3559. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1904 25 of 29
162. Zaliova, M.; Moorman, A.V.; Cazzaniga, G.; Stanulla, M.; Harvey, R.C.; Roberts, K.G.; Heatley, S.L.; Loh, M.L.;
Konopleva, M.; Chen, I.M.; et al. Characterization of leukemias with ETV6-ABL1 fusion. Haematologica 2016,
101, 1082–1093. [CrossRef] [PubMed]
163. De Keersmaecker, K.; Graux, C.; Odero, M.D.; Mentens, N.; Somers, R.; Maertens, J.; Wlodarska, I.;
Vandenberghe, P.; Hagemeijer, A.; Marynen, P.; et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic
leukemia with cryptic t(9;14)(q34;q32). Blood 2005, 105, 4849–4852. [CrossRef] [PubMed]
164. Quintás-Cardama, A.; Tong, W.; Manshouri, T.; Vega, F.; Lennon, P.A.; Cools, J.; Gilliland, D.G.; Lee, F.;
Cortes, J.; Kantarjian, H.; et al. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive
T cell malignancies. Leukemia 2008, 22, 1117–1124. [CrossRef] [PubMed]
165. De Keersmaecker, K.; Versele, M.; Cools, J.; Superti-Furga, G.; Hantschel, O. Intrinsic differences between
the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. Leukemia
2008, 22, 2208–2216. [CrossRef] [PubMed]
166. O’Hare, T.; Eide, C.A.; Deininger, M.W. Bcr-Abl kinase domain mutations, drug resistance, and the road to
a cure for chronic myeloid leukemia. Blood 2007, 110, 2242–2249. [CrossRef] [PubMed]
167. Hoesel, B.; Schmid, J.A. The complexity of NF-κB signaling in inflammation and cancer. Mol. Cancer 2013,
12, 86. [CrossRef] [PubMed]
168. Gerondakis, S.; Fulford, T.S.; Messina, N.L.; Grumont, R.J. NF-κB control of T cell development. Nat. Immunol.
2013, 15, 15–25. [CrossRef] [PubMed]
169. Voll, R.E.; Jimi, E.; Phillips, R.J.; Barber, D.F.; Rincon, M.; Hayday, A.C.; Flavell, R.A.; Ghosh, S. NF-Kappa
B Activation by the pre-T Cell receptor serves as a selective survival signal in T lymphocyte development.
Immunity 2000, 13, 677–689. [CrossRef]
170. Jimi, E.; Strickland, I.; Voll, R.E.; Long, M.; Ghosh, S. Differential role of the transcription factor NF-kappaB
in selection and survival of CD4+ and CD8+ thymocytes. Immunity 2008, 29, 523–537. [CrossRef] [PubMed]
171. Long, M.; Park, S.G.; Strickland, I.; Hayden, M.S.; Ghosh, S. Nuclear factor-κB modulates regulatory T cell
development by directly regulating expression of Foxp3 transcription factor. Immunity 2009, 31, 921–931.
[CrossRef] [PubMed]
172. Chang, J.-H.; Xiao, Y.; Hu, H.; Jin, J.; Yu, J.; Zhou, X.; Wu, X.; Johnson, H.M.; Akira, S.; Pasparakis, M.; et al.
Ubc13 maintains the suppressive function of regulatory T cells and prevents their conversion into effector-like
T cells. Nat. Immunol. 2012, 13, 481–490. [CrossRef] [PubMed]
173. Sivakumar, V.; Hammond, K.J. L.; Howells, N.; Pfeffer, K.; Weih, F. Differential requirement for Rel/nuclear
factor kappa B family members in natural killer T cell development. J. Exp. Med. 2003, 197, 1613–1621.
[CrossRef] [PubMed]
174. Stankovic, S.; Gugasyan, R.; Kyparissoudis, K.; Grumont, R.; Banerjee, A.; Tsichlis, P.; Gerondakis, S.;
Godfrey, D.I. Distinct roles in NKT cell maturation and function for the different transcription factors in the
classical NF-κB pathway. Immunol. Cell Biol. 2011, 89, 294–303. [CrossRef] [PubMed]
175. Kordes, U.; Krappmann, D.; Heissmeyer, V.; Ludwig, W.D.; Scheidereit, C. Transcription factor NF-kappaB
is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000, 14, 399–402. [CrossRef]
[PubMed]
176. Poglio, S.; Cahu, X.; Uzan, B.; Besnard-Guerin, C.; Lapillonne, H.; Leblanc, T.; Baruchel, A.;
Landman-Parker, J.; Petit, A.; Baleydier, F.; et al. Rapid childhood T-ALL growth in xenograft models
correlates with mature phenotype and NF-kappaB pathway activation but not with poor prognosis. Leukemia
2015, 29, 977–980. [CrossRef] [PubMed]
177. Vilimas, T.; Mascarenhas, J.; Palomero, T.; Mandal, M.; Buonamici, S.; Meng, F.; Thompson, B.; Spaulding, C.;
Macaroun, S.; Alegre, M.L.; et al. Targeting the NF-κB signaling pathway in NOTCH1-induced T-cell
leukemia. Nat. Med. 2007, 13, 70–77. [CrossRef] [PubMed]
178. Espinosa, L.; Cathelin, S.; D’Altri, T.; Trimarchi, T.; Statnikov, A.; Guiu, J.; Rodilla, V.; Ingles-Esteve, J.;
Nomdedeu, J.; Bellosillo, B.; et al. The NOTCH/Hes1 pathway sustains NF-kappaB activation through
CYLD repression in T cell leukemia. Cancer Cell 2010, 18, 268–281. [CrossRef] [PubMed]
179. Dos Santos, N.R.; Williame, M.; Gachet, S.; Cormier, F.; Janin, A.; Weih, D.; Weih, F.; Ghysdael, J.
RelB-dependent stromal cells promote T-cell leukemogenesis. PLoS ONE 2008, 3, e2555. [CrossRef] [PubMed]
180. O’Neil, J.; Ventura, J.-J.; Cusson, N.; Kelliher, M. NF-kappaB activation in premalignant mouse tal-1/scl
thymocytes and tumors. Blood 2003, 102, 2593–2596. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1904 26 of 29
181. Bellavia, D.; Campese, A.F.; Alesse, E.; Vacca, A.; Felli, M.P.; Balestri, A.; Stoppacciaro, A.; Tiveron, C.;
Tatangelo, L.; Giovarelli, M.; et al. Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma
in NOTCH3 transgenic mice. EMBO J. 2000, 19, 3337–3348. [CrossRef] [PubMed]
182. Scupoli, M.T.; Donadelli, M.; Cioffi, F.; Rossi, M.; Perbellini, O.; Malpeli, G.; Corbioli, S.; Vinante, F.;
Krampera, M.; Palmieri, M.; et al. Bone marrow stromal cells and the upregulation of interleukin-8
production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the
NF-kappaB and JNK/AP-1 pathways. Haematologica 2008, 93, 524–532. [CrossRef] [PubMed]
183. Bertaina, A.; Vinti, L.; Strocchio, L.; Gaspari, S.; Caruso, R.; Algeri, M.; Coletti, V.; Gurnari, C.; Romano, M.;
Cefalo, M.G.; et al. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute
lymphoblastic leukaemia of childhood. Br. J. Haematol. 2017, 176, 629–636. [CrossRef] [PubMed]
184. Pak, E.; Segal, R.A. Hedgehog signal transduction: Key players, oncogenic drivers, and cancer therapy.
Dev. Cell 2016, 38, 333–344. [CrossRef] [PubMed]
185. Mar, B.G.; Amakye, D.; Aifantis, I.; Buonamici, S. The controversial role of the Hedgehog pathway in normal
and malignant hematopoiesis. Leukemia 2011, 25, 1665–1673. [CrossRef] [PubMed]
186. Shah, D.K.; Hager-Theodorides, A.L.; Outram, S.V.; Ross, S.E.; Varas, A.; Crompton, T. Reduced thymocyte
development in sonic hedgehog knockout embryos. J. Immunol. 2004, 172, 2296–2306. [CrossRef] [PubMed]
187. Outram, S.V.; Varas, A.; Pepicelli, C.V.; Crompton, T. Hedgehog signaling regulates differentiation from
double-negative to double-positive thymocyte. Immunity 2000, 13, 187–197. [CrossRef]
188. El Andaloussi, A.; Graves, S.; Meng, F.; Mandal, M.; Mashayekhi, M.; Aifantis, I. Hedgehog signaling
controls thymocyte progenitor homeostasis and differentiation in the thymus. Nat. Immunol. 2006, 7, 418–426.
[CrossRef] [PubMed]
189. Crompton, T.; Outram, S.V.; Hager-Theodorides, A.L. Sonic hedgehog signalling in T-cell development and
activation. Nat. Rev. Immunol. 2007, 7, 726–735. [CrossRef] [PubMed]
190. Drakopoulou, E.; Outram, S.V.; Rowbotham, N.J.; Ross, S.E.; Furmanski, A.L.; Saldana, J.I.;
Hager-Theodorides, A.L.; Crompton, T. Non-redundant role for the transcription factor Gli1 at multiple
stages of thymocyte development. Cell Cycle 2010, 9, 4144–4152. [CrossRef] [PubMed]
191. Irvine, D.A.; Copland, M. Targeting hedgehog in hematologic malignancy. Blood 2012, 119, 2196–2204.
[CrossRef] [PubMed]
192. Amakye, D.; Jagani, Z.; Dorsch, M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer.
Nat. Med. 2013, 19, 1410–1422. [CrossRef] [PubMed]
193. Jagani, Z.; Dorsch, M.; Warmuth, M. Hedgehog pathway activation in chronic myeloid leukemia. Cell Cycle
2010, 9, 3449–3456. [CrossRef] [PubMed]
194. Blotta, S.; Jakubikova, J.; Calimeri, T.; Roccaro, A.M.; Amodio, N.; Azab, A.K.; Foresta, U.; Mitsiades, C.S.;
Rossi, M.; Todoerti, K.; et al. Canonical and noncanonical hedgehog pathway in the pathogenesis of multiple
myeloma. Blood 2012, 120, 5002–5013. [CrossRef] [PubMed]
195. Dierks, C.; Beigi, R.; Guo, G.R.; Zirlik, K.; Stegert, M.R.; Manley, P.; Trussell, C.; Schmitt-Graeff, A.;
Landwerlin, K.; Veelken, H.; et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on
Hedgehog pathway activation. Cancer Cell 2008, 14, 238–249. [CrossRef] [PubMed]
196. Gao, J.; Graves, S.; Koch, U.; Liu, S.; Jankovic, V.; Buonamici, S.; El Andaloussi, A.; Nimer, S.D.; Kee, B.L.;
Taichman, R.; et al. Hedgehog signaling is dispensable for adult hematopoietic stem cell function.
Cell Stem Cell 2009, 4, 548–558. [CrossRef] [PubMed]
197. Dagklis, A.; Demeyer, S.; De Bie, J.; Radaelli, E.; Pauwels, D.; Degryse, S.; Gielen, O.; Vicente, C.;
Vandepoel, R.; Geerdens, E.; et al. Hedgehog pathway activation in T-cell acute lymphoblastic leukemia
predicts response to SMO and GLI1 inhibitors. Blood 2016, 128, 2642–2654. [CrossRef] [PubMed]
198. Dagklis, A.; Pauwels, D.; Lahortiga, I.; Geerdens, E.; Bittoun, E.; Cauwelier, B.; Tousseyn, T.; Uyttebroeck, A.;
Maertens, J.; Verhoef, G.; et al. Hedgehog pathway mutations in T-cell acute lymphoblastic leukemia.
Haematologica 2015, 100, e102–e105. [CrossRef] [PubMed]
199. Merchant, A.A.; Matsui, W. Smoothening the controversial role of hedgehog in hematopoiesis. Cell Stem Cell
2009, 4, 470–471. [CrossRef] [PubMed]
200. Hou, X.; Chen, X.; Zhang, P.; Fan, Y.; Ma, A.; Pang, T.; Song, Z.; Jin, Y.; Hao, W.; Liu, F.; et al. Inhibition
of hedgehog signaling by GANT58 induces apoptosis and shows synergistic antitumor activity with AKT
inhibitor in acute T cell leukemia cells. Biochimie 2014, 101, 50–59. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1904 27 of 29
201. Katoh, Y.; Katoh, M. Integrative genomic analyses on GLI1: Positive regulation of GLI1 by Hedgehog-GLI,
TGFβ-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by NOTCH-CSL-HES/HEY, and
GPCR-Gs-PKA signals. Int. J. Oncol. 2009, 35, 187–192. [CrossRef] [PubMed]
202. Gu, D.; Xie, J. Non-canonical HH signaling in cancer-current understanding and future directions. Cancers
2015, 7, 1684–1698. [CrossRef] [PubMed]
203. Li, H.; Rao, A.; Hogan, P.G. Interaction of calcineurin with substrates and targeting proteins. Trends Cell Biol.
2011, 21, 91–103. [CrossRef] [PubMed]
204. Macian, F. NFAT proteins: Key regulators of T-cell development and function. Nat. Rev. Immunol. 2005,
5, 472–484. [CrossRef] [PubMed]
205. Bueno, O.F.; Brandt, E.B.; Rothenberg, M.E.; Molkentin, J.D. Defective T cell development and function
in calcineurin A β-deficient mice. Proc. Natl. Acad. Sci. USA 2002, 99, 9398–9403. [CrossRef] [PubMed]
206. Neilson, J.R.; Winslow, M.M.; Hur, E.M.; Crabtree, G.R. Calcineurin B1 is essential for positive but not
negative selection during thymocyte development. Immunity 2004, 20, 255–266. [CrossRef]
207. Avni, O.; Lee, D.; Macian, F.; Szabo, S.J.; Glimcher, L.H.; Rao, A. T(H) cell differentiation is accompanied
by dynamic changes in histone acetylation of cytokine genes. Nat. Immunol. 2002, 3, 643–651. [CrossRef]
[PubMed]
208. Macián, F.; García-Cózar, F.; Im, S.H.; Horton, H.F.; Byrne, M.C.; Rao, A. Transcriptional mechanisms
underlying lymphocyte tolerance. Cell 2002, 109, 719–731. [CrossRef]
209. Gachet, S.; Ghysdael, J. Calcineurin/NFAT signaling in lymphoid malignancies. Gen. Physiol. Biophys. 2009,
28, F47–F54. [PubMed]
210. Marafioti, T.; Pozzobon, M.; Hansmann, M.L.; Ventura, R.; Pileri, S.A.; Roberton, H.; Gesk, S.; Gaulard, P.;
Barth, T.F.; Du, M.Q.; et al. The NFATc1 transcription factor is widely expressed in white cells and translocates
from the cytoplasm to the nucleus in a subset of human lymphomas. Br. J. Haematol. 2005, 128, 333–342.
[CrossRef] [PubMed]
211. Mancini, M.; Toker, A. NFAT proteins: Emerging roles in cancer progression. Nat. Rev. Cancer 2009, 9, 810–820.
[CrossRef] [PubMed]
212. Robbs, B.K.; Cruz, A.L.; Werneck, M.B.; Mognol, G.P.; Viola, J.P. Dual roles for NFAT transcription factor
genes as oncogenes and tumor suppressors. Mol. Cell. Biol. 2008, 28, 7168–7181. [CrossRef] [PubMed]
213. Medyouf, H.; Alcalde, H.; Berthier, C.; Guillemin, M.C.; dos Santos, N.R.; Janin, A.; Decaudin, D.; de Thé, H.;
Ghysdael, J. Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia.
Nat. Med. 2007, 13, 736–741. [CrossRef] [PubMed]
214. Gachet, S.; Genescà, E.; Passaro, D.; Irigoyen, M.; Alcalde, H.; Clémenson, C.; Poglio, S.; Pflumio, F.; Janin, A.;
Lasgi, C.; et al. Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia.
Leukemia 2013, 27, 2289–2300. [CrossRef] [PubMed]
215. Musson, R.E.; Cobbaert, C.M.; Smit, N.P. Molecular diagnostics of calcineurin-related pathologies. Clin. Chem.
2012, 58, 511–522. [CrossRef] [PubMed]
216. Passaro, D.; Irigoyen, M.; Catherinet, C.; Gachet, S.; De Jesus, C.D.C.; Lasgi, C.; Ghysdael, J. CXCR4 Is
required for leukemia-initiating cell activity in T cell acute lymphoblastic leukemia. Cancer Cell 2015,
27, 769–779. [CrossRef] [PubMed]
217. Christopher, M.J.; Liu, F.; Hilton, M.J.; Long, F.; Link, D.C. Suppression of CXCL12 production by bone
marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood 2009,
114, 1331–1339. [CrossRef] [PubMed]
218. Sahin, A.O.; Buitenhuis, M. Molecular mechanisms underlying adhesion and migration of hematopoietic
stem cells. Cell Adhes. Migr. 2012, 6, 39–48. [CrossRef] [PubMed]
219. Pitt, L.A.; Tikhonova, A.N.; Hu, H.; Trimarchi, T.; King, B.; Gong, Y.; Sanchez-Martin, M.; Tsirigos, A.;
Littman, D.R.; Ferrando, A.A.; et al. CXCL12-producing vascular endothelial niches control acute T cell
leukemia maintenance. Cancer Cell 2015, 27, 755–768. [CrossRef] [PubMed]
220. Burns, J.M.; Summers, B.C.; Wang, Y.; Melikian, A.; Berahovich, R.; Miao, Z.; Penfold, M.E.; Sunshine, M.J.;
Littman, D.R.; Kuo, C.J.; et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival,
cell adhesion, and tumor development. J. Exp. Med. 2006, 203, 2201–2213. [CrossRef] [PubMed]
221. Balabanian, K.; Lagane, B.; Infantino, S.; Chow, K.Y.; Harriague, J.; Moepps, B.; Arenzana-Seisdedos, F.;
Thelen, M.; Bachelerie, F. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor
RDC1 in T lymphocytes. J. Biol. Chem. 2005, 280, 35760–35766. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1904 28 of 29
222. Melo, R.C.C.; Longhini, A.L.; Bigarella, C.L.; Baratti, M.O.; Traina, F.; Favaro, P.; de Melo Campos, P.; Saad, S.T.
CXCR7 is highly expressed in acute lymphoblastic leukemia and potentiates CXCR4 response to CXCL12.
PLoS ONE 2014, 9, e85926. [CrossRef] [PubMed]
223. Tosello, V.; Saccomani, V.; Yu, J.Y.; Bordin, F.; Amadori, A.; Piovan, E. Calcineurin complex isolated from T-cell
acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K
whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death. Oncotarget 2016,
7, 45715–45729. [CrossRef] [PubMed]
224. Tosello, V.; Bordin, F.; Yu, J.; Agnusdei, V.; Indraccolo, S.; Basso, G.; Amadori, A.; Piovan, E. Calcineurin and
GSK-3 inhibition sensitizes T-cell acute lymphoblastic leukemia cells to apoptosis through X-linked inhibitor
of apoptosis protein degradation. Leukemia 2016, 30, 812–822. [CrossRef] [PubMed]
225. Shibasaki, F.; Price, E.R.; Milan, D.; McKeon, F. Role of kinases and the phosphatase calcineurin in the nuclear
shuttling of transcription factor NF-AT4. Nature 1996, 382, 370–373. [CrossRef] [PubMed]
226. Beals, C.R.; Sheridan, C.M.; Turck, C.W.; Gardner, P.; Crabtree, G.R. Nuclear export of NF-ATc enhanced by
glycogen synthase kinase-3. Science 1997, 275, 1930–1934. [CrossRef] [PubMed]
227. Engelman, J.A. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations.
Nat. Rev. Cancer 2009, 9, 550–562. [CrossRef] [PubMed]
228. McCubrey, J.A.; Steelman, L.S.; Bertrand, F.E.; Davis, N.M.; Sokolosky, M.; Abrams, S.L.; Montalto, G.;
D’Assoro, A.B.; Libra, M.; Nicoletti, F.; et al. GSK-3 as potential target for therapeutic intervention in cancer.
Oncotarget 2014, 5, 2881–2911. [CrossRef] [PubMed]
229. Luis, T.C.; Ichii, M.; Brugman, M.H.; Kincade, P.; Staal, F.J. Wnt signaling strength regulates normal
hematopoiesis and its deregulation is involved in leukemia development. Leukemia 2012, 26, 414–421.
[CrossRef] [PubMed]
230. Malhotra, S.; Kincade, P.W. Wnt-related molecules and signaling pathway equilibrium in hematopoiesis.
Cell Stem Cell 2009, 4, 27–36. [CrossRef] [PubMed]
231. Polakis, P. Wnt signaling in cancer. Cold Spring Harb. Perspect. Biol. 2012, 4, a008052. [CrossRef] [PubMed]
232. Van Amerongen, R.; Nusse, R. Towards an integrated view of Wnt signaling in development. Development
2009, 136, 3205–3214. [CrossRef] [PubMed]
233. Staal, F.J.; Famili, F.; Garcia Perez, L.; Pike-Overzet, K. Aberrant Wnt Signaling in Leukemia. Cancers 2016, 8,
78. [CrossRef] [PubMed]
234. Guo, Z.; Dose, M.; Kovalovsky, D.; Chang, R.; O’Neil, J.; Look, A.T.; von Boehmer, H.; Khazaie, K.; Gounari, F.
β-catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes
thymocytes to malignant transformation. Blood 2007, 109, 5463–5472. [CrossRef] [PubMed]
235. Ng, O.H.; Erbilgin, Y.; Firtina, S.; Celkan, T.; Karakas, Z.; Aydogan, G.; Turkkan, E.; Yildirmak, Y.;
Timur, C.; Zengin, E.; et al. Deregulated WNT signaling in childhood T-cell acute lymphoblastic leukemia.
Blood Cancer J. 2014, 4, e192. [CrossRef] [PubMed]
236. Tiemessen, M.M.; Baert, M.R.; Schonewille, T.; Brugman, M.H.; Famili, F.; Salvatori, D.C.; Meijerink, J.P.;
Ozbek, U.; Clevers, H.; van Dongen, J.J.; et al. The nuclear effector of Wnt-signaling, Tcf1, functions as
a T-cell-specific tumor suppressor for development of lymphomas. PLoS Biol. 2012, 10, e1001430. [CrossRef]
[PubMed]
237. Yu, S.; Zhou, X.; Steinke, F.C.; Liu, C.; Chen, S.C.; Zagorodna, O.; Jing, X.; Yokota, Y.; Meyerholz, D.K.;
Mullighan, C.G.; et al. The TCF-1 and LEF-1 transcription factors have cooperative and opposing roles in
T cell development and malignancy. Immunity 2012, 37, 813–826. [CrossRef] [PubMed]
238. Spaulding, C.; Reschly, E.J.; Zagort, D.E.; Yashiro-Ohtani, Y.; Beverly, L.J.; Capobianco, A.; Pear, W.S.;
Kee, B.L. NOTCH1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas. Blood 2007,
110, 2650–2658. [CrossRef] [PubMed]
239. Gutierrez, A.; Sanda, T.; Ma, W.; Zhang, J.; Grebliunaite, R.; Dahlberg, S.; Neuberg, D.; Protopopov, A.;
Winter, S.S.; Larson, R.S.; et al. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood 2010,
115, 2845–2851. [CrossRef] [PubMed]
240. Giambra, V.; Jenkins, C.E.; Lam, S.H.; Hoofd, C.; Belmonte, M.; Wang, X.; Gusscott, S.; Gracias, D.; Weng, A.P.
Leukemia stem cells in T-ALL require active Hif1α and Wnt signaling. Blood 2015, 125, 3917–3927. [CrossRef]
[PubMed]
241. Martinez-Outschoorn, U.E.; Peiris-Pages, M.; Pestell, R.G.; Sotgia, F.; Lisanti, M.P. Cancer metabolism:
A therapeutic perspective. Nat. Rev. Clin. Oncol. 2017, 14, 11–31. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1904 29 of 29
242. Spencer, J.A.; Ferraro, F.; Roussakis, E.; Klein, A.; Wu, J.; Runnels, J.M.; Zaher, W.; Mortensen, L.J.; Alt, C.;
Turcotte, R.; et al. Direct measurement of local oxygen concentration in the bone marrow of live animals.
Nature 2014, 508, 269–273. [CrossRef] [PubMed]
243. Hale, L.P.; Braun, R.D.; Gwinn, W.M.; Greer, P.K.; Dewhirst, M.W. Hypoxia in the thymus: Role of oxygen
tension in thymocyte survival. Am. J. Physiol. Heart Circ. Physiol. 2002, 282, H1467–H1477. [CrossRef]
[PubMed]
244. Boag, J.M.; Beesley, A.H.; Firth, M.J.; Freitas, J.R.; Ford, J.; Hoffmann, K.; Cummings, A.J.; de Klerk, N.H.;
Kees, U.R. Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemia. Leukemia 2006,
20, 1731–1737. [CrossRef] [PubMed]
245. Altman, B.J.; Stine, Z.E.; Dang, C.V. From Krebs to clinic: Glutamine metabolism to cancer therapy.
Nat. Rev. Cancer 2016, 16, 619–634. [CrossRef] [PubMed]
246. Xiao, B.; Heath, R.; Saiu, P.; Leiper, F.C.; Leone, P.; Jing, C.; Walker, P.A.; Haire, L.; Eccleston, J.F.; Davis, C.T.;
et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature 2007,
449, 496–500. [CrossRef] [PubMed]
247. Shackelford, D.B.; Shaw, R.J. The LKB1-AMPK pathway: Metabolism and growth control in tumour
suppression. Nat. Rev. Cancer 2009, 9, 563–575. [CrossRef] [PubMed]
248. Hardie, D.G.; Ross, F.A.; Hawley, S.A. AMPK: A nutrient and energy sensor that maintains energy
homeostasis. Nat. Rev. Mol. Cell. Biol. 2012, 13, 251–262. [CrossRef] [PubMed]
249. Faubert, B.; Boily, G.; Izreig, S.; Griss, T.; Samborska, B.; Dong, Z.; Dupuy, F.; Chambers, C.; Fuerth, B.J.;
Viollet, B.; et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo.
Cell Metab. 2013, 17, 113–124. [CrossRef] [PubMed]
250. Hirsch, H.A.; Iliopoulos, D.; Tsichlis, P.N.; Struhl, K. Metformin selectively targets cancer stem cells, and acts
together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69, 7507–7511.
[CrossRef] [PubMed]
251. Grimaldi, C.; Chiarini, F.; Tabellini, G.; Ricci, F.; Tazzari, P.L.; Battistelli, M.; Falcieri, E.; Bortul, R.; Melchionda, F.;
Iacobucci, I.; et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute
lymphoblastic leukemia: Therapeutic implications. Leukemia 2012, 26, 91–100. [CrossRef] [PubMed]
252. Sengupta, T.K.; Leclerc, G.M.; Hsieh-Kinser, T.T.; Leclerc, G.J.; Singh, I.; Barredo, J.C. Cytotoxic effect
of 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) on childhood acute lymphoblastic
leukemia (ALL) cells: Implication for targeted therapy. Mol. Cancer 2007, 6, 46. [CrossRef] [PubMed]
253. Leclerc, G.M.; Leclerc, G.J.; Kuznetsov, J.N.; DeSalvo, J.; Barredo, J.C. Metformin induces apoptosis through
AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts. PLoS ONE 2013, 8, e74420. [CrossRef]
[PubMed]
254. Liu, L.; Ulbrich, J.; Muller, J.; Wustefeld, T.; Aeberhard, L.; Kress, T.R.; Muthalagu, N.; Rycak, L.; Rudalska, R.;
Moll, R.; et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 2012,
483, 608–612. [CrossRef] [PubMed]
255. Moiseeva, O.; Bourdeau, V.; Roux, A.; Deschenes-Simard, X.; Ferbeyre, G. Mitochondrial dysfunction
contributes to oncogene-induced senescence. Mol. Cell. Biol. 2009, 29, 4495–4507. [CrossRef] [PubMed]
256. Saito, Y.; Chapple, R.H.; Lin, A.; Kitano, A.; Nakada, D. AMPK Protects Leukemia-initiating cells in myeloid
leukemias from metabolic stress in the bone marrow. Cell Stem Cell 2015, 17, 585–596. [CrossRef] [PubMed]
257. Blagih, J.; Coulombe, F.; Vincent, E.E.; Dupuy, F.; Galicia-Vazquez, G.; Yurchenko, E.; Raissi, T.C.; van der
Windt, G.J.; Viollet, B.; Pearce, E.L.; et al. The energy sensor AMPK regulates T cell metabolic adaptation and
effector responses in vivo. Immunity 2015, 42, 41–54. [CrossRef] [PubMed]
258. Accordi, B.; Galla, L.; Milani, G.; Curtarello, M.; Serafin, V.; Lissandron, V.; Viola, G.; te Kronnie, G.; De
Maria, R.; Petricoin, E.F., 3rd; et al. AMPK inhibition enhances apoptosis in MLL-rearranged pediatric
B-acute lymphoblastic leukemia cells. Leukemia 2013, 27, 1019–1027. [CrossRef] [PubMed]
259. Kishton, R.J.; Barnes, C.E.; Nichols, A.G.; Cohen, S.; Gerriets, V.A.; Siska, P.J.; Macintyre, A.N.;
Goraksha-Hicks, P.; de Cubas, A.A.; Liu, T.; et al. AMPK is essential to balance glycolysis and mitochondrial
metabolism to control T-ALL cell stress and survival. Cell Metab. 2016, 23, 649–662. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
